



GUIDELINE

Donor heart selection: Evidence-based guidelines for providers

Hannah Copeland, MD,^{a,b} Ivan Knezevic, MD,^c David A. Baran, MD,^d Vivek Rao, MD,^{e,f} Michael Pham, MD, MPH,^g Finn Gustafsson, MD,^h Sean Pinney, MD,ⁱ Brian Lima, MD,^j Marco Masetti, MD,^k Agnieszka Ciarka, MD,^{l,m} Navin Rajagopalan, MD,ⁿ Adriana Torres, MD,^o Eileen Hsich, MD,^p Jignesh K. Patel, MD,^q Livia Adams Goldraich, MD,^r Monica Colvin, MD,^s Javier Segovia, MD, PhD,^t Heather Ross, MD,^{f,g} Mahazarin Ginwalla, MD,^u Babak Sharif-Kashani, MD,^v MaryJane A. Farr, MD,^w Luciano Potena, MD,^k Jon Kobashigawa, MD,^q Maria G. Crespo-Leiro, MD,^x Natasha Altman, MD,^y Florian Wagner, MD,^z Jennifer Cook, MD,^{aa} Valentina Stosor, MD,^{bb} Paolo A. Grossi, MD, PhD,^{cc} Kiran Khush, MD,^{dd} Tahir Yagdi, MD,^{ee} Susan Restaino, MD,^{ff,gg} Steven Tsui, MD,^{hh} Daniel Absi, MD,ⁱⁱ George Sokos, DO,^{jj} Andreas Zuckermann, MD,^{kk} Brian Wayda, MD,^{dd} Joost Felius, PhD,^{ll,mm} and Shelley A. Hall, MD^{mm,nn}

From the ^aDepartment of Cardiovascular and Thoracic Surgery Lutheran Hospital, Fort Wayne, Indiana; ^bIndiana University School of Medicine-Fort Wayne, Fort Wayne, Indiana; ^cTransplantation Centre, University Medical Centre Ljubljana, Ljubljana, Slovenia; ^dDepartment of Medicine, Division of Cardiology, Sentara Heart Hospital, Norfolk, Virginia; ^ePeter Munk Cardiac Centre Toronto General Hospital, Toronto, Ontario, Canada; ^fUniversity of Toronto, Toronto, Ontario, Canada; ^gSutter Health California Pacific Medical Center, San Francisco, California; ^hRigshospitalet, University of Copenhagen, Copenhagen, Denmark; ⁱUniversity of Chicago Medicine, Chicago, Illinois; ^jMedical City Heart Hospital, Dallas, Texas; ^kHeart Failure and Heart Transplant Unit IRCCS Policlinico di S. Orsola, Bologna, Italy; ^lDepartment of Cardiovascular Diseases, Katholieke Universiteit Leuven, Leuven, Belgium; ^mInstitute of Civilisation Diseases and

Project Leaders: Hannah Copeland, MD, Ivan Knezevic, MD, and Shelley A. Hall, MD.

Task Force 1 Co-Chairs: David A. Baran, MD, and Vivek Rao, MD.

Task Force 2 Co-Chairs: Navin Rajagopalan, MD, and Adriana Torres, MD.

Task Force 3 Co-Chairs: Monica Colvin, MD and Javier Segovia, MD.

Task Force 4 Co-Chairs: Jon Kobashigawa, MD, and Luciano Potena, MD.

Task Force 5 Co-Chairs: Kiran Khush, MD, and Tahir Yagdi, MD.

Abbreviations: ACAOS, anomalous origination of a coronary artery from the opposite sinus; ACC, American College of Cardiologists; BMI, body mass index; BNP, B-type natriuretic peptide; CABG, coronary artery bypass graft; CAD, coronary artery disease; CAV, cardiac allograft vasculopathy; CNS, central nervous system; CO, carbon monoxide; COVID-19, coronavirus disease 2019; CPR, cardiopulmonary resuscitation; CT, computed tomography; ECG, electrocardiogram; ECMO, extracorporeal membrane oxygenation; HIV, human immunodeficiency virus; HLA, human leukocyte antigens; INTERMACS, interagency registry for mechanically assisted circulatory

support; ISHLT, International Society for Heart and Lung Transplantation; INH, isonicotinic acid hydrazide; LV, left ventricle; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; MRI, magnetic resonance imaging; NT-proBNP, N-terminal prohormone of B-type natriuretic peptide; OPO, organ procurement organization; OPTN, organ procurement and transplantation network; PCI, percutaneous coronary intervention; PGD, primary graft dysfunction; pHM, predicted heart mass; PLSVC, persistent left superior vena cava; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TTE, transthoracic echocardiography; UNOS, united network for organ sharing; VA, veno-arterial; VAD, ventricular assist device; VV, veno-venous; WHO, World Health Organization

Reprint requests: Hannah Copeland, MD, University School of Medicine - Fort Wayne (IUSM-FW), Lutheran Hospital 7910 W, Jefferson Boulevard, MOB 2, Suite 102, Fort Wayne, IN 46804. Telephone: 260-458-3556. Fax: 260-458-3568.

E-mail address: hannahcopeland411@gmail.com

Regenerative Medicine, University of Information Technology and Management, Rzeszow, Poland; ^uUniversity of Kentucky, Lexington, Kentucky; ^oLos Cobos Medical Center, Universidad El Bosque, Bogota, Colombia; ^pCleveland Clinic, Cleveland, Ohio; ^qCedars Sinai Smidt Heart Institute, Los Angeles, California; ^rHospital de Clinicas de Porto Alegre, Porto Alegre, Brazil; ^sUniversity of Michigan, Ann Arbor, Michigan; ^tCardiology Department, Hospital Universitario Puerta de Hierro, Universidad Autónoma de Madrid, Madrid, Spain; ^uCardiovascular Division, Palo Alto Medical Foundation/Sutter Health, Burlingame, California; ^vDepartment of Cardiology, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^wDepartment of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas; ^xUniversity Hospital Complex of La Coruña (CIBERCV), La Coruña, Spain; ^yUniversity of Colorado, Aurora, Colorado; ^zUniversity of Hamburg, Hamburg, Germany; ^{aa}University of Cincinnati, Cincinnati, Ohio; ^{bb}Northwestern University Feinberg School of Medicine, Chicago, Illinois; ^{cc}University of Insubria, Varese, Italy; ^{dd}Division of Cardiovascular Medicine, Stanford University, Stanford, California; ^{ee}Department of Cardiovascular Surgery, Ege University School of Medicine, Izmir, Turkey; ^{ff}Division of Cardiology Columbia University, New York, New York; ^{gg}New York Presbyterian Hospital, New York, New York; ^{hh}Department of Cardiothoracic Surgery Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom; ⁱⁱDepartment of Cardiothoracic and Transplant Surgery, University Hospital Favaloro Foundation, Buenos Aires, Argentina; ^{jj}Heart and Vascular Institute, West Virginia University, Morgantown, West Virginia; ^{kk}Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria; ^{ll}Baylor Scott & White Research Institute, Dallas, Texas; ^{mm}Texas A&M University Health Science Center, Dallas, Texas; and the ⁿⁿDivision of Transplant Cardiology, Mechanical Circulatory Support and Advanced Heart Failure, Baylor University Medical Center, Dallas, Texas.

KEYWORDS:

donor heart;
heart transplant;
donor risk factors;
selection;
brain death

The proposed donor heart selection guidelines provide evidence-based and expert-consensus recommendations for the selection of donor hearts *following brain death*. These recommendations were compiled by an international panel of experts based on an extensive literature review.

J Heart Lung Transplant 000;000:1–23

© 2022 International Society for Heart and Lung Transplantation. All rights reserved.

In 1995, Dr J. Copeland noted that “only optimal donors should be accepted for heart transplantation,” implying that extended-criteria donor organs may not be viable.¹ Despite this awareness raised from over 25 years ago, this topic has remained much debated. While older donors are more routinely used in Europe, younger donors with short ischemic times are more commonly used in the United States. Mortality rates differ worldwide, and some of these differences are due to donor selection and/or recipient urgency. Seeking a balance between maximizing the number of transplants (by taking greater risk) and minimizing the risk to meet societal needs, while controlling cost, is difficult and frequently related to a lack of reliable data regarding both donors and recipients. The issue is further complicated by the fact that the peri-operative surgical risk is a combination of risk factors that include donor, recipient, and ischemic time. Lastly, meaningful comparisons of transplant outcomes across countries require proper risk-adjustment.

The proposed guidelines provide evidence-based as well as expert-consensus recommendations for the selection of donors *following brain death*. These recommendations were compiled by an international panel of experts based on an extensive literature review. Controversial subjects are dealt with one by one and current state-of-the-art information is provided to help define risk. The strength of each recommendation and the corresponding level of available evidence were classified following the International Society for Heart and Lung Transplantation protocol for developing guideline documents.²

Task forces were established with an international panel of experts. The task forces reviewed donor characteristics (Task force 1), international donor practices (Task force 2), donor and recipient matched characteristics (Task force 3), extended donor characteristics (Task force 4), and donor risk scores (Task force 5).

Clinical stability of the donor

Factors considered in the clinical stability of the cardiac donor are hemodynamics, hormonal resuscitation,³⁻¹¹ and the restoration of intravascular volume and electrolyte imbalance,¹²⁻²² as well as donor metabolism.

Recommendations for donor hemodynamics:^{21,23-31}

Class I

1. Donors receiving low dose norepinephrine (e.g., ≤ 0.1 $\mu\text{g}/\text{kg}/\text{min}$) may be considered suitable for transplantation if (other) inotropes are not required. In general, the higher the dose of norepinephrine in the donor, the poorer the expected outcome after transplant. **Level of Evidence: C.**

Class IIa

1. If inotropes and/or vasopressors are required to maintain adequate circulatory function in the donor, placement of

a Swan-Ganz catheter and goal-directed therapy should be considered to maximize the likelihood of donor heart utilization. **Level of Evidence: C.**

2. Suggested hemodynamic targets for donor hearts include the following:

- Mean arterial pressure >60 mm Hg
- Cardiac index >2.4 liter/min/m²
- Central venous pressure <12 mm Hg
- Pulmonary capillary wedge pressure <12 mm Hg
- Left ventricular (LV) stroke work index >15 g·min/m²

Level of Evidence: C.

Recommendations considering donor metabolism:^{27,30,32-34}

Class IIa

1. Use of hearts from donors with moderately abnormal serum sodium (outside the 135-145 mEq/liter range) may be considered. **Level of Evidence: C.**
2. Hearts from donors with extreme hypo- or hypernatremia (serum sodium <129 or ≥170 mEq/liter, respectively) should not be used. **Level of Evidence: C.**
3. Donor hyperglycemia should not be a contraindication to use for heart transplantation. **Level of Evidence: C.**

Mechanisms of donor death

The mode of brain death affects clinical outcomes following heart transplantation.^{23,35-37} Recommendations are provided for donor death by carbon monoxide (CO) poisoning, explosive brain death, and unexplained causes. Furthermore, the pathophysiology of brain death includes neurohormonal and inflammatory changes that may result in donor organ injury. Beneficial effects of corticosteroid administration to brain-dead donors (hormonal resuscitation therapy) in terms of organ recovery, graft survival, and graft function have been reported, but there are many confounding factors that preclude definitive assessment of the utility of steroid administration during donor management.³⁻⁵

Recommendations regarding donor death by CO poisoning:³⁸⁻⁴⁸

Class IIa

1. Donors with CO poisoning should be carefully screened. Risk factors for early heart allograft dysfunction include ischemic electrocardiogram (ECG) changes, troponin I elevations ≥0.7 ng/ml and left ventricular dysfunction. **Level of Evidence: C.**

Class III

1. Donors with CO poisoning and carboxyhemoglobin levels >40%, ischemic ECG changes, elevated levels of

cardiac troponin (≥0.7 ng/ml) or ventricular dysfunction should generally be avoided. **Level of Evidence: C.**

Recommendation regarding explosive brain death:^{23,35-37,49-53}

Class IIa

1. Donors with explosive brain death may be considered for transplantation. There is evidence suggesting reduced long-term survival of recipients of such donors, possibly due to increased cardiac allograft vasculopathy. **Level of Evidence: C.**

Unexplained cause of donor death

Few reports have been published detailing the outcomes of allografts taken from donors with an unexplained cause of death. When faced with such an offer, centers should consider the more common causes of sudden death in young persons.

Recommendation for the evaluation of unexplained causes of death

Class IIb

1. Donors with unexplained cause of sudden death should be carefully screened with ECG and, when appropriate, coronary angiography for cardiac causes of death including hypertrophic cardiomyopathy, long-QT syndrome, Brugada syndrome, and congenital heart disease includes coronary anomalies. Donors with unexplained sudden death can be considered for transplant if the evaluation is negative. **Level of Evidence: C.**

Donor demographics

Recommendations for donor age:⁵⁴⁻⁷⁰

Class I

1. The use of donor hearts <45 years of age is recommended. **Level of Evidence: C.**
2. Donors ≥45 years of age can be used after screening for significant coronary artery disease (e.g., ≤50% narrowing) and if short ischemic times (<4 hours) can be expected. Such screening criteria vary around the world based on risk factors and average population donor characteristics. Considerations should take into account estimated survival benefit, availability of organs, the severity of illness of the recipient, and whether the recipient is on mechanical circulatory support. No established upper age limit currently exists. **Level of Evidence: C.**

Class IIa

1. Donor selection should account for unique recipient characteristics such as older donors to be used in older or highly sensitized recipients (smaller compatible donor pool) who have a negative crossmatch (either prospective or virtual depending on needs of recipient and/or institution) to the prospective older donor. **Level of Evidence: C.**

Donor size

Factors considered in developing guidelines on donor size were sex matching,⁷¹⁻⁷⁵ donor weight and height,^{64,72,74,76-78} predicted heart mass (pHM),^{63,69,79} the role of body mass index,^{75,80} oversizing for pulmonary hypertension,^{76,81,82} and extreme donor-recipient size mismatch.^{63,74,81,83} While there currently is no consensus as to best method of determining size matching, pHM is gaining in popularity.

Recommendations regarding donor size**Class I**

1. Allocation of female donors to male recipients may be done safely, especially in recipients without pulmonary hypertension and when adequate donor/recipient weight ratio and/or pHM are ensured. A value of pHM within 20% to 30% of recipient is considered acceptable. **Level of Evidence: C.**

Class IIb

1. Due to the impact on right ventricular dysfunction of the donor allograft, pulmonary hypertension in the intended recipient should be taken into consideration when determining the degree of acceptable size and sex mismatch. **Level of Evidence: C.**

Recommendation on anti-human leukocyte antigens (HLA) compatibility:^{68,75,76,84}**Class IIa**

1. The presence of preformed human leukocyte antigens (HLA) antibodies should be ascertained and compared against the donor HLA, at least virtually, prior to acceptance for organ transplant. **Level of Evidence: C.**
2. There currently is no agreed-upon standard for which HLA antibodies can be crossed and which should be avoided. Center practice varies based on magnitude, strength of antibodies, whether they are C1q positive (e.g., complement-fixing), and the level of experience with managing sensitization and ability to absorb transplant center risk. **Level of Evidence: C.**

Recommendations on blood group compatibility between donor and recipient:^{75,85-87}

(See also [Table 1](#).)

Class I

1. ABO blood group compatibility should be confirmed. **Level of Evidence: C.**
2. Systems of care should be implemented to assure that blood group compatibility is not violated without a specific reason (ABO-incompatible pediatric transplantation). **Level of Evidence: C.**

Recommendations regarding ischemic time:^{59,62,68,88-109}**Class I**

1. Target total organ ischemic time for cardiac transplantation should be ≤ 4 hours, to reduce the risk of primary graft dysfunction and early death. **Level of Evidence: C.**

Class IIa

1. A transplant center may allow the total organ ischemic time to exceed 4 hours for donors <45 years of age without compromising early outcomes after heart transplantation. With older donors, it is specifically recommended to avoid long-distance transportation or other factors (e.g., redo sternotomy, ventricular assist device (VAD) explantation, which can cause prolonged operative times) that could result in total donor ischemic times >4 hours. **Level of Evidence: C.**
2. Ex-vivo normothermic heart perfusion platforms can be safely used to decrease ischemic time for distant procurements and potentially to expand the procurement of marginal donors based on metabolic evaluation during ex-vivo perfusion. **Level of Evidence: C.**

Donor comorbidities**Recommendations for left ventricular hypertrophy (LVH)**^{55,59,81,106,110-115} **and hypertension:**^{54,68,113,116,117}

(See [Table 2](#) for the gradation of left ventricular hypertrophy (LVH).)

Table 1 Compatible Blood Groups

Recipient blood type	Compatible donor
A	A, O
B	B, O
AB	A, B, AB, O
O	O

Table 2 LVH Determined by Measurement of the Interventricular Septum

Level of LVH	Intraventricular septum
Mild	11-13 mm
Moderate	14-16 mm
Severe	≥17 mm

Class I

1. LVH should be assessed by measuring the thickness of the interventricular septum or the posterior wall on echocardiography. **Level of Evidence: C.**

Class IIa

1. Carefully selected donor hearts with LVH >13 mm (measured as outlined above) may be considered, particularly with younger (donors ≤40 years of age) and/or shorter ischemic time (<4 hours). **Level of Evidence: C.**
2. Chronic hypertension (defined by contemporary guidelines) or the use of hearts from donors being treated for hypertension in the absence of LVH do not appear to impact post-transplant outcomes. **Level of Evidence: C.**

Recommendations regarding donors with coronary artery disease (CAD): ^{55,118-124}

(Table 3 illustrates how recommendations have varied over time and across geographic regions.)

Class IIa

1. Donors with mild luminal irregularities (e.g., ≤50% narrowing) on coronary angiography may be considered for heart transplantation. **Level of Evidence: C.**
2. Coronary angiography should be considered in donors ≥45 years old, depending on geography and other risk factors. See also Table 3. **Level of Evidence: C.**

3. Risk factors suggesting need for coronary angiography include hypertension, diabetes (particularly with longer time of treatment), male sex, obesity, hyperlipidemia, tobacco and/or cocaine/methamphetamine use. **Level of Evidence: C.**
4. Myocardial bridging is rarely a contraindication to transplantation. **Level of Evidence: C**

Class IIb

1. Donors with single-vessel coronary disease amenable to percutaneous or surgical therapy may be considered after balancing the risk of coronary disease progression and the urgency of the recipient. **Level of Evidence: C.**
2. Donors with left main and/or 2 to 3 vessel obstructive (≥50%) coronary disease are best avoided for transplantation in the absence of extenuating circumstances. **Level of Evidence: C.**

Recommendations regarding donors with diabetes: ^{54,55,58,59,68,69,81,116,117,128-131}**Class IIa**

1. Donors with diabetes mellitus and no other risk factors, particularly without coronary artery disease, can be safely used. **Level of Evidence: C.**
2. Coronary angiography should be considered for diabetic donors, and duration of diabetes and donor age should be carefully weighed. **Level of Evidence: C.**

Recommendations regarding donor experiencing cardiopulmonary arrest and the duration of cardiopulmonary resuscitation (CPR): ¹³²⁻¹³⁸**Class IIa**

1. Donors with cardiopulmonary resuscitation may be used if heart function is normal (by left ventricular ejection fraction (LVEF) and hemodynamics) at the time of

Table 3 Recommended Age Criteria for the Use of Coronary Angiography in Donor Evaluation Across Time and Geographic Region (Class IIa/b; Level of Evidence: C)

Publication	Recommended age for men	Recommended age for women	Region	Year
ACC Recommendations ¹²⁵	<ul style="list-style-type: none"> • Age >45 years • Lower by 5-10 years if risk factors present 	<ul style="list-style-type: none"> • Age >50 years • Lower by 5-10 years if risk factors present 	US	1993
Maximizing Use of Organs Recovered From the Cadaver Donor Consensus Conference ²⁷	<ul style="list-style-type: none"> • Age >55 years: mandatory • Age >45 years: recommended • Age >35 years if cocaine or 3 risk factors 	<ul style="list-style-type: none"> • Age >55 years: mandatory • Age >50 years: recommended • Age >40 years if cocaine or 3 risk factors 	US	2002
United Network for Organ Sharing ¹²⁶	<ul style="list-style-type: none"> • Age >40 years • Younger with risk factors 	<ul style="list-style-type: none"> • Age >45 years • Younger with risk factors 	US	2018
European Committee on Organ Transplantation (Council of Europe) ¹²⁷	<ul style="list-style-type: none"> • Age >55 years • Age >45 years if more than 1 risk factor present 	<ul style="list-style-type: none"> • Age >55 years • Age >45 years if more than 1 risk factor present 	Europe	2018

procurement, unless the cardiac arrest circumstances raise the suspicion for underlying structural heart disease. **Level of Evidence: C.**

- The duration of donor cardiopulmonary arrest and of the CPR alone should not be used to exclude donor hearts for transplantation. CPR times >30 minutes in both adult and pediatric donors do not negatively impact post-transplant survival or outcomes if echocardiographic cardiac function and hemodynamics are favorable (e.g., LVEF >50%) after resuscitation. **Level of Evidence: C.**

Donor drug use

Recommendation regarding donor tobacco use: ¹³⁹⁻¹⁴⁴

Class IIa

- Tobacco use of significant pack-years increases the risk of donor coronary artery disease (CAD). Depending on donor age (>45 years), obtaining a donor angiogram may be reasonable. **Level of Evidence: C.**

Recommendation regarding donor alcohol use: ¹⁴⁵⁻¹⁵³

Class IIa

- The hearts of donors with a history of alcohol use may be used for transplantation if cardiac function is preserved on echocardiography. **Level of Evidence: C.**

Recommendations regarding donor use of illicit drugs (cocaine, amphetamine, methamphetamine): ^{140,154-160}

Class IIa

- Donors with a history of cocaine use can be considered for heart transplantation if there is no significant LVH (i.e., ≥ 14 mm; see also the recommendations on donor LVH in this document). **Level of Evidence: C.**

- Donors with a history of past or active cocaine use should have a coronary angiogram when possible. **Level of Evidence: C.**
- Donors with toxicology positive for amphetamine or methamphetamine may be utilized for transplant if ventricular function and structure are normal on echocardiogram and imaging. **Level of Evidence: C.**
- Donors with toxicology positive for multiple substances may be utilized for transplant if ventricular function and structure are normal on echocardiogram and imaging. **Level of Evidence: C.**

Infections in the donor

This section reviews various potential infections in a donor though it is not comprehensive of all possibilities. Infectious disease thoracic transplant physician specialists should be consulted for unique donor infections as new pathogens are always emerging and treatments are constantly evolving.

Recommendation regarding bacterial infections in the donor: ^{63,161-165}

Class IIa

- Transplantation of hearts from bacteremic donors is feasible, provided that the recipient, after being informed of the associated risks, is treated with targeted antimicrobials for an appropriate duration post-transplant. **Level of Evidence: C.**

Recommendations regarding fungal infections: ¹⁶⁶⁻¹⁷³

(See Table 4.)

Recommendations regarding bloodborne viral infections in the donor

(Recommendations concerning donors with hepatitis B, ^{127,174-188} hepatitis C, ¹⁸⁹⁻¹⁹⁸ and human immunodeficiency virus (HIV) ¹⁹⁹⁻²⁰⁷ are summarized in Table 5.)

Table 4 Fungal Infections

Pathogen	Recommendation	Strength/level of evidence
Aspergillus, active	If disseminated, do not utilize	III /C
Aspergillus, active (lung only)	If lung only, consider taking heart with post-transplant prophylaxis	IIb /C
Aspergillus, history of disease	If findings, send workup to rule out active disease, possible post-transplant prophylaxis	IIa /C
Coccidiomycosis, active disease	Do not utilize	III /C
Coccidiomycosis, history of disease	If findings, send workup to rule out active disease, possible post-transplant prophylaxis	IIa /C
Cryptococcus, untreated	Do not utilize	III /C
Cryptococcus, actively treated	Consider risks/benefits	IIa /C
Histoplasmosis, active disease	Do not utilize	III /C
Histoplasmosis, history of disease	If findings, send workup to rule out active disease	IIa /C

Table 5 Bloodborne Infections

Pathogen	Recommendation	Strength/level of evidence
Hepatitis B Ag+	Should be limited to carefully selected, consented recipients.	IIa /C
Hepatitis B cAb+	With appropriate post-transplant monitoring and prophylaxis, HBcAb + donor organs may be used for transplantation.	IIa /C
Hepatitis C (anti-HCV+, HCV-RNA-)	Generally safe for transplantation but requires post-transplant HCV-RNA monitoring.	IIa /C
Hepatitis C (anti-HCV+, HCV RNA+)	Should be limited to consented recipients with appropriate post-transplant treatment and monitoring.	IIa /C
HIV	Transplantation of HIV seropositive hearts into HIV seropositive recipients is reasonable with full informed consent and involvement of local infectious disease experts in advance.	IIa /C

Table 6 Recommendation Regarding Donors with Tuberculosis

Pathogen	Recommendation	Strength/level of evidence
Mycobacterium tuberculosis, active disease	Consider taking organ, consult infectious disease specialist for follow up and isonicotinic acid hydrazide (INH) for 6 months	IIb /C
Mycobacterium tuberculosis, history of disease	Accept organ, consult infectious disease specialist for follow up and consider INH 3-6 months	IIa /C

Recommendation regarding donors with tuberculosis:²⁰⁸

(See Table 6.)

Recommendation regarding donors with increased infection risk:^{127,193,209-226}

(See also Table 7.)

Table 7 Behavioral, Social, Medical, and Other Factors that Increase Risk for Recent Hepatitis B, Hepatitis C, or HIV Infection in Organ Donors Per US Guidelines²¹⁷

Risk criteria (in the preceding 30 days):

- Sex^a with a person known or suspected to have HIV, HBV, HCV infection
- Man who has had sex with another man
- Sex in exchange for money or drugs
- Sex with a person who had sex in exchange for money or drugs
- Drug injection for non-medical reasons
- Sex with a person who injected drugs for non-medical reasons
- Incarceration (confinement in jail, prison, or a juvenile correctional facility) for ≥ 72 consecutive hours
- Child breastfed by a mother with HIV infection
- Child born to a mother with HIV, HBV, or HCV infection
- People in whom medical and social histories cannot be obtained or is unknown

^aThe term sex refers to vaginal, anal or oral sexual contact.

Class I

1. Carefully selected donors at increased risk for unrecognized/recent hepatitis B, hepatitis C, and HIV may be selected for transplantation with surveillance post-transplant for disease transmission. **Level of Evidence: B.**

Recommendations regarding emerging viral pathogens:²²⁷⁻²⁴³

(See Table 8.)

Recommendations regarding parasitic infections in the donor:^{180,244-252}

(See Table 9.)

Recommendations regarding central nervous system infections in the donor:^{253,254}

(See Table 10.)

Malignancies in the donor

Recommendations regarding malignancy in donors:²⁵⁵⁻²⁶¹

(See also Table 11.)

Class IIa

1. Donors with non-melanoma skin cancers and low-grade primary central nervous system tumors should be

Table 8 Emerging Viruses

Virus	Recommendation	Strength /level of evidence
SARS-CoV-2, active confirmed	Should be limited to informed recipients. Ideally should be offered to immunized recipients or with perioperative prophylaxis. ^a	IIb /C
SARS-CoV-2, recovered	Can be utilized for informed recipients. Ideally should be offered to immunized recipients or with perioperative therapies. ^a	IIb /C
West Nile virus, IgM+, NAT+, active confirmed	Do not utilize.	III /C
West Nile virus, IgG+, history of disease	Consider utilization	IIa/C
Zika virus, IgM+, active confirmed	Do not utilize.	III /C
Zika virus, IgG+, history of disease	Consider utilization	IIb/C

^aAs COVID-19 therapies are rapidly evolving, so is the utilization of these donors.

Table 9 Parasitic Infections

Infection	Recommendation	Strength /level of evidence
<i>Trypanosoma cruzii</i> (Chagas disease) confirmed	Do not utilize.	III /C
<i>Strongyloides stercoralis</i>	May be used with prophylaxis and surveillance post-transplant.	IIa /C

Table 10 CNS Infections

Infection	Recommendation	Strength /level of evidence
Viral meningoencephalitis	Do not utilize.	III /C
Fungal meningoencephalitis	Do not utilize.	III /C
Amebic meningoencephalitis	Do not utilize.	III /C
Bacterial meningitis	Donors with treated bacterial meningitis are suitable for heart transplantation.	IIa /C

considered favorably as potential donors because the risk of cancer transmission is low. **Level of Evidence: C.**

- The tumor type, histology, disease stage, disease-free interval, and the recipient's risk of dying on the waiting list should be considered when making decisions regarding the suitability of organs for transplantation. **Level of Evidence: C.**

Class IIb

- Donors with a history of melanoma, choriocarcinoma, breast or colon adenocarcinoma, lymphoma, or leukemia are considered at high risk for transmission. **Level of Evidence: C.**
- There should be high level of suspicion for a metastatic tumor in potential donors with a past history of malignancy who experience a nontraumatic cerebral hemorrhage. In such cases, a thorough thoracic and abdominal exploration is recommended before recovering organs for transplantation, with possible biopsy and pathologic evaluation. **Level of Evidence: C.**

Diagnostic studies

Cardiac biomarkers

The measurement of biomarkers is an established method of predicting risk for many cardiovascular conditions, including myocardial injury and heart failure, and has drawn considerable interest in the assessment of organ donors. B-type Natriuretic Peptide (BNP), NT-proBNP, and troponin are elevated after brain death, particularly subarachnoid hemorrhage, likely due to increased sympathetic activity and release of catecholamines with associated elevated wall stress and myocardial injury.^{263,264}

Recommendations regarding troponin: ²⁶⁵⁻²⁶⁸

Class IIb

- Coronary angiography should be considered for potential donors with significantly increased troponin concentrations (with quantitative limits being institution-

Table 11 Risks and Recommendations Regarding Malignancy (By Risk and Tumor Type) for the Utilization of Donor Hearts²⁶²

Risk category	Tumor characteristics	Recommended clinical use	Strength/level of evidence
No significant risk	Benign tumors in which malignancy is excluded	Standard donor	IIa /C
Minimal risk (<0.1% transmission)	<ul style="list-style-type: none"> • Basal cell carcinoma, skin • Squamous cell carcinoma, skin without metastases • Carcinoma <i>in situ</i>, skin (non-melanoma) • <i>In situ</i> cervical carcinoma • <i>In situ</i> vocal cord carcinoma • Superficial (noninvasive) papillary carcinoma of bladder (TONOMO by the TNM staging system) (nonrenal transplant only) • Solitary papillary thyroid carcinoma, ≤0.5 cm • Minimally invasive follicular carcinoma, thyroid, ≤ 1.0 cm • (Resected) solitary renal cell carcinoma, ≤1.0 cm, well differentiated (Fuhrman 1-2) 	Clinical judgment with informed consent	IIa /C
Low risk (0.1-1% transmission)	<ul style="list-style-type: none"> • (Resected) solitary renal cell carcinoma, >1.0 cm ≤2.5 cm, well differentiated (Fuhrman 1-2) • Low grade CNS tumor (WHO grade I or II) • Primary CNS mature teratoma • Solitary papillary thyroid carcinoma, 0.5-2.0 cm • Minimally invasive follicular carcinoma, thyroid, 1.0-2.0 cm • History of treated non-CNS malignancy (≥5 years prior) with >99% probability of cure 	Use in recipients at significant risk without transplant. Informed consent required	IIa /C
Intermediate risk (1-10% transmission)	<ul style="list-style-type: none"> • Breast carcinoma (stage 0, i.e., carcinoma in situ) • Colon carcinoma (stage 0, i.e., carcinoma in situ) • (Resected) solitary renal cell carcinoma T1b (4-7 cm) well differentiated (Fuhrman 1-2) stage I • History of treated non-CNS malignancy (≥5 years prior) with probability of cure between 90% and 99% 	Use of these donors is generally not recommended. Lifesaving transplant may be acceptable in circumstances where recipient expected survival without transplantation is short (e.g., a few days or less). Informed consent required.	IIb /C
High Risk (>10% transmission)	<ul style="list-style-type: none"> • Malignant melanoma • Breast carcinoma >stage 0 (active) • Colon carcinoma >stage 0 (active) • Choriocarcinoma • CNS tumor (any) with ventriculoperitoneal or ventriculoatrial shunt, surgery (other than uncomplicated biopsy), irradiation or extra-CNS metastasis • CNS Tumor WHO grade III or IV • Leukemia or lymphoma • History of melanoma, leukemia or lymphoma, small cell lung/neuroendocrine carcinoma • Any other history of treated non-CNS malignancy either (a) insufficient follow-up to predict behavior, (b) considered incurable or (c) with probability of cure <90% • Metastatic carcinoma • Sarcoma • Lung cancer (stages I-IV) • Renal cell carcinoma >7cm or stage II-IV • Small cell/neuroendocrine carcinoma, any site of origin • Active cancer not listed elsewhere 	Use of these donors is discouraged except in rare and extreme circumstances. Informed consent required and consult with oncology may be desired.	III /C

dependent) depending on clinical context of donor cause of death and risk factors for CAD. **Level of Evidence: C.**

2. Troponin levels may be elevated (with quantitative limits being institution-dependent) following brain death but are not independent reasons to decline a donor. Correlation with echocardiography and clinical scenario is necessary. **Level of Evidence: C.**

Recommendation regarding B-type natriuretic peptide (BNP) and NT-proBNP: ^{269,270}

Class IIa

1. BNP levels may be elevated following brain death but are not independent reasons to decline a donor. Correlation with echocardiography and clinical scenario is necessary. **Level of Evidence: C.**

Recommendation for cardiac imaging: ²⁷¹⁻²⁸¹

Class I

1. Echocardiography should be conducted and imaging available for review as part of donor evaluation. **Level of Evidence: C.**
2. Serial echocardiography in donors with initial LV dysfunction after brain death may be useful to identify donors with reversible LV dysfunction. **Level of Evidence: C.**
3. Computed tomography (CT) angiography for coronary artery disease is a reasonable alternative to traditional angiography in some centers. **Level of Evidence: C.**

Recommendation for pharmacological stress echocardiography: ^{272,277,280}

Class IIa

1. Pharmacologic stress echo may be used in the assessment of dysfunctional donor hearts to distinguish between CAD or subclinical cardiomyopathy and reversible left ventricular dysfunction. **Level of Evidence: C.**

Recommendation for strain rate imaging: ²⁸²⁻²⁸⁸

Class IIa

1. Myocardial strain echo may assist to distinguishing between ischemic and stunned myocardium. **Level of Evidence: C.**

Recommendation for contrast-enhanced 3D echocardiography: ^{276,278,279,281}

Class IIa

1. Use of echo contrast agents should be considered to improve myocardial visualization when images are sub-optimal. **Level of Evidence: C.**

Recommendation for cardiac magnetic resonance imaging (MRI): ²⁸⁹⁻²⁹¹

Class IIb

1. Cardiac MRI is a useful option for visualization of structure and function of donor hearts, but availability and ease of performance limit its use. **Level of Evidence: C.**

Coronary angiography

While there are no evidence-based findings with respect to coronary angiography, it is reasonable to consider performing this test in donors who are considered to have high risk for coronary artery disease.

Recommendation for coronary angiography

Class IIb

1. A coronary angiogram should be obtained in donors at high risk of CAD, such as age >45 years and those with diabetes or tobacco use or illicit drug use (e.g., cocaine, amphetamine, methamphetamine). **Level of Evidence: C.**

The rational use of donor hearts meeting extended criteria

Utilization of extended-criteria donor hearts has the aim to expand use while mitigating recipient risk. Considerable debate exists on how to define “extended criteria” with the greatest emphasis on traditional risk factors such as increased donor age, left ventricular dysfunction, left ventricular hypertrophy, and prolonged ischemic time.^{263,292,293} These risk factors, as well as others (diabetes, hypertension, death due to stroke), have been evaluated in single-center studies and in analyses of large databases such as the UNOS registry.^{59,294} However, careful evaluation of the data would suggest that a closer look is warranted.

Recommendation for the utilization of extended-criteria donor hearts: ^{59,127,294-296}

Class IIa

1. For recipients who are challenging to match (e.g., highly sensitized patients, patients on temporary circulatory support, VAD complications) consideration of an extended-criteria donor may be lifesaving. Acceptance of such donors should be considered in the context of concurrent risk factors. **Level of Evidence: C.**

Recommendation regarding the use of donor hearts with low ejection fraction: ^{62,67,74,75,106,113,117,120,271,273,274,294,297-316}

(See also [Table 12](#)).

Table 12 Recommendations for the Use of Donor Hearts with Ventricular Abnormalities

Donor concern	Recommended intervention	Outcomes	Strength/level of evidence
LVEF <45%	Dobutamine stress echocardiography, repeat transthoracic echocardiography (TTE)	Ventricular wall augmentation predicts improvement in LVEF	IIa /C
LVH >1.4 cm	None	Poor outcomes if concurrent donor age >55 years and ischemic time \geq 4 hours ¹⁰⁶	IIa /B
Donor/recipient size mismatch	Calculate predicted heart mass (pHM)	Lower survival with pHM difference >10%-15% ⁷⁴	IIa /B
Donor CAD	Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)	Slightly lower survival in 1 vessel disease, worse survival in multi-vessel disease ¹²⁰	IIa/C

Class IIa

1. Hearts with an initially low LVEF, especially from young brain-dead donors, should be aggressively pursued. It is reasonable to repeat echocardiographic assessments to determine improvement of such donors.

Level of Evidence: C.

2. It is reasonable to consider a heart with reduced but improved LVEF in the setting of a young donor especially for recipients with an urgent clinical need (e.g., INTERMACS Class 1 or 2), balancing risks and benefits. **Level of Evidence: C.**

Recommendation regarding the use of donor hearts with valvular abnormalities^{27,311,317-328}

Class III

1. In the case of some donor valvular defects (e.g., mild-to-moderate mitral or tricuspid insufficiency), a pre-transplant surgical repair strategy may be considered appropriate for very severely ill patients at extremely high risk of death. This strategy can be considered especially for recipients who are challenging to match (e.g., highly sensitized patients, patients on short-term mechanical support or with VAD complications). **Level of Evidence: C.**

Recommendation regarding donors with prior transplant:³²⁹

Class IIa

1. Donors with prior non-cardiac solid organ transplants may be utilized for heart transplantation. **Level of Evidence: C.**

Prior chest surgery in the donor

Few, if any, published reports exist on outcomes of cardiac transplantation using donors with prior chest surgery (e.g., thoracotomy). In such instances, radiographic evaluation via chest computed topography scan would be necessary to

determine proximity of mediastinal structures to the sternum and technical planning for chest reentry.

Recommendation regarding donors with prior chest surgery

Class IIa

1. Donors with prior thoracic surgery may be utilized for heart transplantation with careful screening and preoperative review. **Level of Evidence: C.**

Recommendations regarding donors on extracorporeal membrane oxygenation (ECMO):^{330,331}

Class IIa

1. Donors with veno-venous extracorporeal membrane oxygenation (ECMO) support may be utilized for heart transplantation. **Level of Evidence: C.**

Class IIb

1. Donors with veno-arterial ECMO support due to hemodynamic instability associated with brain death may be utilized for heart transplantation if the organ can be weaned off support. **Level of Evidence: C.**

Recommendation regarding domino transplantation:³³²⁻³³⁴

Class IIa

1. Domino heart transplantation, in which the explanted heart from an en-bloc heart-lung recipient is utilized as a donor organ for a second heart recipient, can be considered with careful consideration of the recipient condition and informed consent from the recipient. **Level of Evidence: C.**

Recommendations regarding donors with persistent left superior vena cava (PLSVC): ³³⁵⁻³⁴⁸

Class IIa

1. Hearts with persistent left superior vena cava (PLSVC) can be used successfully. **Level of Evidence: C.**
2. In case the right superior vena cava is absent or narrow, the donor heart can be utilized in a bi-atrial transplant technique. **Level of Evidence: C.**
3. The left superior vein should in any case be ligated at the entrance to the coronary sinus/ left atrium. In the case of PLSVC drainage into the coronary sinus a close examination of the coronary sinus roof (and closure) from the left atrial side is necessary to avoid right-to-left cardiac shunt after transplantation. **Level of Evidence: C.**

Recommendations regarding coronary artery anomalies in the donor: ³⁴⁹⁻³⁵⁸

Class IIa

1. Unexplained ischemia or regional wall motion abnormalities after transplantation should be promptly evaluated by angiography to determine if anomalous origination of a coronary artery from the opposite sinus (ACAOS) was present in the donor. **Level of Evidence: C.**

Class III

1. Donor hearts with ACAOS should not be utilized. **Level of Evidence: C.**

Recommendations regarding donors with patent foramen ovale: ^{327,359-363}

Class I

1. Screening for inter-atrial shunts should be performed routinely by visual examination, palpation of the donor heart, and routine probe examination of the atrial septum. **Level of Evidence: C.**
2. All atrial septal defects should be securely closed at the time of procurement. **Level of Evidence: C.**

Donor characteristics and risk scores

Multiple risk scores have been developed in an attempt to address donor risk,⁵⁵ recipient risk, and the combination of recipient and donor risks^{55,92,364} with the potential of using these risks to drive allocation.³⁶⁵ Validation of these risk scores has been established via associations with mortality outcomes.^{55,366-369}

Table 13 summarizes all published risk scores (as identified in a recent meta-analysis³⁷⁰) that aim to inform allocation and donor selection. These scores incorporate donor characteristics into the prediction of post-transplant

Table 13 Summary of Published Risk Prediction Scores that Incorporate Donor Characteristics

Source	Donor variables included											C-statistic in external validation
	Ischemic time	Age	Sex or sex-mismatch	Size or size-mismatch	Diabetes mellitus	Hepatitis C infection	Inopressor dose	Cause of death	Blood group (ABO)	# other donor factors	# recipient factors	
Anyanwu 1999 ³⁷⁴	x	x	x	x	x		x			1	7	-
Hong 2011 ⁹²	x	x	x	x	x					9	12	0.56-0.58
Weiss 2012 ⁵⁹	x	x								2	0	0.54-0.55
Smits 2012 ⁵⁵	x						x	x		8	0	-
Nilsson 2015 ³⁷⁵	x	x		x				x		4	32	0.59-0.63
Johnston 2016 ³⁷⁶	x	x								1	8	0.60-0.64
Trivedi 2016 ³⁷⁷	x	x								0	9	-
Joyce 2018 ³⁷⁸	x	x								0	8	-
Yoon 2018 ³⁷⁹	x	x		x	x					1	21	-
Jasseron 2019 ⁸¹	x	x								0	7	-

Level of evidence: C (For all risk score models).
 An "x" indicates the inclusion of a given donor risk factor in the corresponding risk score. "Size" refers to donor height and/or weight either in absolute terms or relative to that of the recipient. The listed donor factors consist of all that were included in more than one risk score. For scores that have been validated in a distinct (non-derivation) cohort, the range of reported c-statistics across published validation studies is listed.

mortality, either in isolation or in conjunction with recipient factors. While the majority of these risk scores include donor age, ischemic time, and sex (and/or sex-mismatch), the selection of donor characteristics is otherwise highly variable. External validation (when performed) indicates that these scores have limited predictive ability. Accordingly, they should not be considered definitive or substitute for clinical judgement, but may compliment a more holistic assessment of potential donors.

In general, the different allocation systems in place throughout the world may influence the decision of how much donor risk to take in individual cases.³⁷¹⁻³⁷³

International donor heart selection practices

A shortage of donor organs exists throughout the world. Factors accounting for this shortage vary among countries and include lack of awareness about organ donation, lack of organ donor registries,³⁸⁰ evolving donor allocation policies, as well as logistical, legal, religious, and political barriers. Donor and recipient demographics also vary by geographical region and change over time. In an analysis of global organ donation rates, the highest donor rates were in countries with an organized health care donation system. This was more important than socio-economic factors or the human development index.³⁸¹ In countries with well-established transplant programs and national donor registries, a variety of strategies have been employed in an attempt to increase the supply of donor organs, mostly centered on variations of either opt-in or opt-out consenting guidelines for the potential donor and their family and the associated legislation. In general, a country's selection criteria and utilization rates are impacted by unique social and environmental factors such as aging of the population, fatality causes and rates, cultural and religious beliefs regarding the donation process or geographic constraints.

Recommendations regarding international donor heart selection practices: ^{117,302,315,380-414}

Class I

1. Education strategies including donor awareness campaigns, e-campaigns, the capability to register for organ donation on mobile phones and social media can improve organ donation and should include OPOs. **Level of Evidence: C.**
2. National organized processes for organ allocation are most effective. **Level of Evidence: C.**

Class IIb

1. Neither "opt-in" (where there is a requirement to sign up to register to be an organ donor) nor "opt-out" (where organ donation will occur by default unless a specific request is made prior to death for organs not to be taken; also known as "presumed consent") has demonstrated superiority in donor organ utilization. **Level of Evidence: C.**

2. The decision to change donation consent from opt-in to opt-out likely has to be part of a broader nationwide strategy to increase organ donation rates which includes promotional campaigns, organizational changes, infra-structural support. **Level of Evidence: C.**
3. Prioritizing transplant candidates for those individuals who have agreed to be potential organ donors is another strategy proposed to promote organ donation ("reciprocal altruism"). **Level of Evidence: C.**
4. Data sharing among countries is encouraged in order to enhance the knowledge in the field of donor heart selection. Those analyses may provide data to identify opportunities for broadening of donor pools while maintaining optimal long-term outcomes. **Level of Evidence: C.**

Class III

1. Financial incentives to donors and their families, such as payment for cells, tissues, and organs, are discouraged because they likely take unfair advantage of the poorest and most vulnerable groups, undermine altruistic donations, and lead to profiteering and human trafficking. **Level of Evidence: C.**

Limitations

This document includes recommendations for the selection of donors following brain death. The utilization of donor hearts following circulatory death has been restricted, until recently, to relatively small areas of the world. While its application is currently becoming more wide-spread, there is not enough consensus yet to form recommendations.

The recommendations herein are based on professional opinion and, if available, on published data, mostly consisting of retrospective single-institution studies. The recommendations must be taken in the context of regional donor availability which varies worldwide. For example, the age of the available donor pool differs widely among countries. Centers, physicians, and surgeons, must select the best donor for the recipient, based on the urgency of the candidate list for transplant, the severity of the candidate's illness, risk of dying on the waitlist, all within the context of available donors and the degree of regulatory oversight (or lack thereof) that can hinder or augment donor acceptance rates. This also means that not all recommendations listed herein are equally relevant for all parts of the world based on practices and on donor and recipient demographics. Furthermore, if the risk factors present in a given donor are outside the geographically accepted "normal," then additional informed consent from recipient may be required.

Conclusion

This document establishes a foundation of knowledge about donor risk factors, which physicians, surgeons, transplant clinicians, and transplant centers may use as a guide when evaluating a donor heart. All donor heart selection must be evaluated in the context of the heart transplant candidate and what risk is acceptable to that individual.

Disclosure statement

Hannah Copeland MD: Consultant for Paragonix, Speaker for Abbott. Ivan Knezevic, MD: Consultant and Surgical Proctor for Abbott and SynCardia. David A. Baran, MD: Consultant for Getinge, Abbott, Abiomed, Livanova; Steering Committee for Procyrion, CareDx, Speaker Pfizer, Novartis. Vivek Rao, MD: Consultant for Gore, Abbott, Medtronic; Member of North American Surgical Advisory Board for Medtronic. Michael Pham, MD, MPH: None. Marco Masetti, MD: None. Finn Gustafsson, MD: Advisor for Amgen, Bayer, Inoio, Alnylam, Pfizer, Abbott, Boehringer-Ingelheim, Pharmacosmos; Speaker fees from Astra-Zeneca, Orion Pharma, Novartis. Agnieszka Ciarka, MD: None. Sean Pinney, MD: Consulting fees from Abbott, CareDx, Medtronic, Procyrion, Transmedics; Honoraria from Boston Scientific. Brian Lima, MD: None. Navin Rajagopalan, MD: Consulting fee from CareDx. Adriana Torres, MD: None. Eileen Hsich, MD: Honoraria from Natera. Jignesh Patel, MD: Consulting fees from Akcea Inc, Alnylam Pharmaceuticals, Pfizer, CareDx, Natera, Eidos/BridgeBio; Speakers Bureau for Akcea Inc, Alnylam Pharmaceuticals, Pfizer; Research funding from Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Pfizer, BridgeBio. Livia Adams Goldraich, MD: None. Monica Colvin, MD: Advisor for Sanofi, Natera, Alnylam. Javier Segovia, MD, PhD: None. Heather Ross, MD: None. Mahazarin Ginwalla, MD: None. Babak Sharif-Kashani, MD: None. Mary Jane Farr, MD: None. Luciano Potena, MD: Speakers honoraria from Novartis, Astra Zeneca and Abbott; Advisory board for Novartis and Biotest. Jon Kobashigawa, MD: None. Maria Crespo-Leiro, MD: Research support from Novartis, Vifor Pharma, and FEDER Funds; Personal fees (travel grants, lecture fees and advisory boards) from Novartis, Abbott Vascular, Astellas, Vifor Pharma, AstraZeneca, MSD, Lilly and Boehringer Ingelheim. Natasha Altman, MD: None. Florian Wagner, MD: None. Jennifer Cook, MD: Consultant for Eko and Itamar Medical. Valentina Stosor, MD: Grant support paid to institution from Eli Lilly & Company; Honorarium from Med Learning Group for educational lectures. Paolo Grossi, MD, PhD: Member of Advisory Board for Merck, Sharp and Dohme, Biotest, Allovir, Takeda; Speaker bureau for MSD, Gilead, Atara, Takeda, Astellas. Kiran K. Khush, MD, MAS: Grant funding from National Institutes of Health; Scientific Advisor for CareDx, Sanofi; Speaker for CareDx. Tahir Yagdi, MD: Consultant for Abbott and Medtronic. Susan Restaino, MD: None. Steven Tsui, MD: Consultant Advisor for British Standards Institute; Chief Medical Officer of 3R Life Sciences Ltd.; Research funding from BioVentrix Inc. Daniel Absi, MD: None. George Sokos, DO: Grant funding National Institutes of Health; Clinical Advisory Board for ChemImage, CardioVere. Andreas Zuckermann, MD: Speaker for Paragonix, Chiesi, Köhler Chemie, Sanofi, Mallinckrodt-Therakos; Grant funding from Chiesi, Biotest. Brian Waida, MD: None. Joost Felius, PhD: None. Shelley Hall, MD: Consultant and Advisory Board for Abbott, Medtronic, Abiomed, CareDx, Natera; Speaker for CareDx.

References

- Copeland JG. Only optimal donors should be accepted for heart transplantation: protagonist. *J Heart Lung Transplant* 1995;14(6 Pt 1):1038-42.
- International Society for Heart Lung Transplantation. Protocol and policies for developing standards statements, guidelines, and consensus documents and for conducting consensus conferences. 2017; https://ishlt.org/ishlt/media/documents/STANDARD-S_AND_GUIDELINES_DEVELOPMENT_PROTOCOL_FINAL.pdf
- Dhar R, Cotton C, Coleman J, et al. Comparison of high- and low-dose corticosteroid regimens for organ donor management. *J Crit Care* 2013;28. 111.e111-117.
- Dupuis S, Amiel JA, Desgroseilliers M, et al. Corticosteroids in the management of brain-dead potential organ donors: a systematic review. *Br J Anaesth* 2014;113:346-59.
- Pinsard M, Ragot S, Mertes PM, et al. Interest of low-dose hydrocortisone therapy during brain-dead organ donor resuscitation: the CORTICOME study. *Crit Care* 2014;18:R158.
- Buchanan IA, Mehta VA. Thyroid hormone resuscitation after brain death in potential organ donors: a primer for neurocritical care providers and narrative review of the literature. *Clin Neurol Neurosurg* 2018;165:96-102.
- Cooper LB, Milano CA, Williams M, et al. Thyroid hormone use during cardiac transplant organ procurement. *Clin Transplant* 2016;30:1578-83.
- Holndonner-Kirst E, Nagy A, Czobor NR, et al. The impact of l-thyroxine treatment of donors and recipients on postoperative outcomes after heart transplantation. *J Cardiothorac Vasc Anesth* 2019;33:1629-35.
- Mi Z, Novitzky D, Collins JF, Cooper DK. The optimal hormonal replacement modality selection for multiple organ procurement from brain-dead organ donors. *Clin Epidemiol* 2015;7:17-27.
- Novitzky D, Mi Z, Sun Q, Collins JF, Cooper DK. Thyroid hormone therapy in the management of 63,593 brain-dead organ donors: a retrospective analysis. *Transplantation* 2014;98:1119-27.
- Roels L, Spaight C, Smits J, Cohen B. Critical care staffs' attitudes, confidence levels and educational needs correlate with countries' donation rates: data from the donor action database. *Transpl Int* 2010;23:842-50.
- Al-Khafaji A, Elder M, Lebovitz DJ, et al. Protocolized fluid therapy in brain-dead donors: the multicenter randomized MOnIToR trial. *Intensive Care Med* 2015;41:418-26.
- Barklin A. Systemic inflammation in the brain-dead organ donor. *Acta Anaesthesiol Scand* 2009;53:425-35.
- Kuecuek O, Mantouvalou L, Klemz R, et al. Significant reduction of proinflammatory cytokines by treatment of the brain-dead donor. *Transplant Proc* 2005;37:387-8.
- McKeown DW, Ball J. Treating the donor. *Curr Opin Organ Transplant* 2014;19:85-91.
- Abdelnour T, Rieke S. Relationship of hormonal resuscitation therapy and central venous pressure on increasing organs for transplant. *J Heart Lung Transplant* 2009;28:480-5.
- Dimopoulou I, Tsagarakis S, Anthi A, et al. High prevalence of decreased cortisol reserve in brain-dead potential organ donors. *Crit Care Med* 2003;31:1113-7.
- Plurad DS, Bricker S, Neville A, Bongard F, Putnam B. Arginine vasopressin significantly increases the rate of successful organ procurement in potential donors. *Am J Surg* 2012;204:856-60. discussion 860-851.
- Hadjizacharia P, Salim A, Brown C, et al. Does the use of pulmonary artery catheters increase the number of organs available for transplantation? *Clin Transplant* 2010;24:62-6.
- Novitzky D, Mi Z, Videla LA, Collins JF, Cooper DK. Hormone resuscitation therapy for brain-dead donors - is insulin beneficial or detrimental? *Clin Transplant* 2016;30:754-9.
- Stoica SC, Satchithananda DK, Charman S, et al. Swan-Ganz catheter assessment of donor hearts: outcome of organs with borderline hemodynamics. *J Heart Lung Transplant* 2002;21:615-22.

22. Saner FH, Kavuk I, Lang H, Radtke A, Paul A, Broelsch CE. Organ protective management of the brain-dead donor. *Eur J Med Res* 2004;9:485-90.
23. Raichlin E, Villarraga HR, Chandrasekaran K, et al. Cardiac allograft remodeling after heart transplantation is associated with increased graft vasculopathy and mortality. *Am J Transplant* 2009;9:132-9.
24. Santise G, D'Ancona G, Falletta C, et al. Donor pharmacological hemodynamic support is associated with primary graft failure in human heart transplantation. *Interact Cardiovasc Thorac Surg* 2009;9:476-9.
25. Angleitner P, Kaider A, Gökler J, et al. High-dose catecholamine donor support and outcomes after heart transplantation. *J Heart Lung Transplant* 2018;37:596-603.
26. von Ziegler F, Helbig S, Kreissl N, Meiser B, Becker A, Kaczmarek I. Norepinephrine versus dopamine pretreatment of potential heart donors - impact on long-term outcome. *Ann Transplant* 2013;18:320-6.
27. Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, Va. *Circulation* 2002;106:836-41.
28. Chamorro C, Silva JA, Segovia J, Romera MA. Use of catecholamines in cardiac donors: what is the real limit? *J Heart Lung Transplant* 2004;23:916-7.
29. Nixon JL, Kfoury AG, Brunisholz K, et al. Impact of high-dose inotropic donor support on early myocardial necrosis and outcomes in cardiac transplantation. *Clin Transplant* 2012;26:322-7.
30. Aliabadi-Zuckermann AZ, Gökler J, Kaider A, et al. Donor heart selection and outcomes: an analysis of over 2,000 cases. *J Heart Lung Transplant* 2018;37:976-84.
31. Benck U, Hoeger S, Brinkkoetter PT, et al. Effects of donor pre-treatment with dopamine on survival after heart transplantation: a cohort study of heart transplant recipients nested in a randomized controlled multicenter trial. *J Am Coll Cardiol* 2011;58:1768-77.
32. Hoefer D, Ruttman-Ulmer E, Smits JM, Devries E, Antretter H, Laufer G. Donor hypo- and hypernatremia are predictors for increased 1-year mortality after cardiac transplantation. *Transpl Int* 2010;23:589-93.
33. Kaczmarek I, Tenderich G, Groetzner J, et al. The controversy of donor serum sodium levels in heart transplantation—a multicenter experience. *Thorac Cardiovasc Surg* 2006;54:313-6.
34. Sally MB, Ewing T, Crutchfield M, et al. Determining optimal threshold for glucose control in organ donors after neurologic determination of death: A United Network for Organ Sharing Region 5 Donor Management Goals Workgroup prospective analysis. *J Trauma Acute Care Surg* 2014;76:62-8. discussion 68-69.
35. Cantin B, Kwok BW, Chan MC, et al. The impact of brain death on survival after heart transplantation: time is of the essence. *Transplantation* 2003;76:1275-9.
36. Cohen O, De La Zerda DJ, Beygui R, Hekmat D, Laks H. Donor brain death mechanisms and outcomes after heart transplantation. *Transplant Proc* 2007;39:2964-9.
37. Mehra MR, Uber PA, Ventura HO, Scott RL, Park MH. The impact of mode of donor brain death on cardiac allograft vasculopathy: an intravascular ultrasound study. *J Am Coll Cardiol* 2004;43:806-10.
38. Bentley MJ, Mullen JC, Lopushinsky SR, Modry DL. Successful cardiac transplantation with methanol or carbon monoxide-poisoned donors. *Ann Thorac Surg* 2001;71:1194-7.
39. Iberer F, Königsrainer A, Wasler A, Petutschnigg B, Auer T, Tscheliessnigg K. Cardiac allograft harvesting after carbon monoxide poisoning Report of a successful orthotopic heart transplantation *J Heart Lung Transplant* 1993;12:499-500.
40. Karwande SV, Hopfenbeck JA, Renlund DG, Burton NA, Gay WA. An avoidable pitfall in donor selection for heart transplantation. *Utah Heart Transplant Program. J Heart Transplant* 1989;8:422-4.
41. Koerner MM, Tenderich G, Minami K, et al. Extended donor criteria: use of cardiac allografts after carbon monoxide poisoning. *Transplantation* 1997;63:1358-60.
42. Luckraz H, Tsui SS, Parameshwar J, Wallwork J, Large SR. Improved outcome with organs from carbon monoxide poisoned donors for intrathoracic transplantation. *Ann Thorac Surg* 2001;72:709-13.
43. Martín-Suárez S, Mikus E, Pilato E, et al. Cardiac transplantation from a carbon monoxide intoxicated donor. *Transplant Proc* 2008;40:1563-5.
44. Roberts JR, Bain M, Klachko MN, Seigel EG, Wason S. Successful heart transplantation from a victim of carbon monoxide poisoning. *Ann Emerg Med* 1995;26:652-5.
45. Rodrigus IE, Conraads V, Amsel BJ, Moulijn AC. Primary cardiac allograft failure after donor carbon monoxide poisoning treated with biventricular assist device. *J Heart Lung Transplant* 2001;20:1345-8.
46. Sezgin A, Akay TH, Ozkan S, Gültekin B. Successful cardiac transplantation from donor with carbon monoxide intoxication: A case report. *Transplant Proc* 2008;40:324-5.
47. Smith JA, Bergin PJ, Williams TJ, Esmore DS. Successful heart transplantation with cardiac allografts exposed to carbon monoxide poisoning. *J Heart Lung Transplant* 1992;11(4 Pt 1):698-700.
48. Satran D, Henry CR, Adkinson C, Nicholson CI, Bracha Y, Henry TD. Cardiovascular manifestations of moderate to severe carbon monoxide poisoning. *J Am Coll Cardiol* 2005;45:1513-6.
49. Shivalkar B, Van Loon J, Wieland W, et al. Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. *Circulation* 1993;87:230-9.
50. Novitzky D. Detrimental effects of brain death on the potential organ donor. *Transplant Proc* 1997;29:3770-2.
51. Stoica SC, Satchithananda DK, White PA, et al. Brain death leads to abnormal contractile properties of the human donor right ventricle. *J Thorac Cardiovasc Surg* 2006;132:116-23.
52. Fracasso T, Meyer P, Hüllin R, Sauerland C, Schmeling A. Pathology of the right ventricle: a comparison between traumatic brain injury, afterload mismatch and cerebral hypoxia. *J Heart Lung Transplant* 2013;32:461-3.
53. Berman M, Ali A, Ashley E, et al. Is stress cardiomyopathy the underlying cause of ventricular dysfunction associated with brain death? *J Heart Lung Transplant* 2010;29:957-65.
54. Lund LH, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report—2013; focus theme: age. *J Heart Lung Transplant* 2013;32:951-64.
55. Smits JM, De Pauw M, de Vries E, et al. Donor scoring system for heart transplantation and the impact on patient survival. *J Heart Lung Transplant* 2012;31:387-97.
56. Axtell AL, Fiedler AG, Chang DC, et al. The effect of donor age on post-transplant mortality in a cohort of adult cardiac transplant recipients aged 18-45. *Am J Transplant* 2019;19:876-83.
57. Bergenfeldt H, Lund LH, Stehlik J, Andersson B, Höglund P, Nilsson J. Time-dependent prognostic effects of recipient and donor age in adult heart transplantation. *J Heart Lung Transplant* 2019;38:174-83.
58. Foroutan F, Alba AC, Guyatt G, et al. Predictors of 1-year mortality in heart transplant recipients: a systematic review and meta-analysis. *Heart* 2018;104:151-60.
59. Weiss ES, Allen JG, Kilic A, et al. Development of a quantitative donor risk index to predict short-term mortality in orthotopic heart transplantation. *J Heart Lung Transplant* 2012;31:266-73.
60. Chew HC, Kumarasinghe G, Iyer A, et al. Primary graft dysfunction after heart transplantation. *Curr Transplant Rep* 2014;1:257-65.
61. Sabatino M, Vitale G, Manfredini V, et al. Clinical relevance of the International Society for Heart and Lung Transplantation consensus classification of primary graft dysfunction after heart transplantation: epidemiology, risk factors, and outcomes. *J Heart Lung Transplant* 2017;36:1217-25.
62. Lund LH, Khush KK, Cherikh WS, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult heart transplantation report-2017; focus theme: allograft ischemic time. *J Heart Lung Transplant* 2017;36:1037-46.
63. Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. *J Heart Lung Transplant* 2010;29:914-56.
64. Weber DJ, Wang IW, Gracon AS, et al. Impact of donor age on survival after heart transplantation: an analysis of the United Network for Organ Sharing (UNOS) registry. *J Card Surg* 2014;29:723-8.

65. Reiss N, LePrince P, Bonnet N, et al. Results after orthotopic heart transplantation accepting donor hearts >50 years: experience at La Pitie Salpetriere, Paris. *Transplant Proc* 2007;39:549-53.
66. Lietz K, John R, Mancini DM, Edwards NM. Outcomes in cardiac transplant recipients using allografts from older donors versus mortality on the transplant waiting list; Implications for donor selection criteria. *J Am Coll Cardiol* 2004;43:1553-61.
67. Roig E, Almenar L, Crespo-Leiro M, et al. Heart transplantation using allografts from older donors: multicenter study results. *J Heart Lung Transplant* 2015;34:790-6.
68. Stehlik J, Feldman DS, Brown RN, et al. Interactions among donor characteristics influence post-transplant survival: a multi-institutional analysis. *J Heart Lung Transplant* 2010;29:291-8.
69. Nagji AS, Hranjec T, Swenson BR, et al. Donor age is associated with chronic allograft vasculopathy after adult heart transplantation: implications for donor allocation. *Ann Thorac Surg* 2010;90:168-75.
70. Bruschi G, Colombo T, Oliva F, et al. Orthotopic heart transplantation with donors greater than or equal to 60 years of age: a single-center experience. *Eur J Cardiothorac Surg* 2011;40:e55-61.
71. Khush KK, Kubo JT, Desai M. Influence of donor and recipient sex mismatch on heart transplant outcomes: analysis of the International Society for Heart and Lung Transplantation Registry. *J Heart Lung Transplant* 2012;31:459-66.
72. Martinez-Selles M, Almenar L, Paniagua-Martin MJ, et al. Donor/recipient sex mismatch and survival after heart transplantation: only an issue in male recipients? An analysis of the Spanish Heart Transplantation Registry. *Transpl Int* 2015;28:305-13.
73. Kaczmarek I, Meiser B, Beiras-Fernandez A, et al. Gender does matter: gender-specific outcome analysis of 67,855 heart transplants. *Thorac Cardiovasc Surg* 2013;61:29-36.
74. Reed RM, Netzer G, Hunsicker L, et al. Cardiac size and sex-matching in heart transplantation: size matters in matters of sex and the heart. *JACC Heart Fail* 2014;2:73-83.
75. Bergenfeldt H, Stehlik J, Hoglund P, Andersson B, Nilsson J. Donor-recipient size matching and mortality in heart transplantation: influence of body mass index and gender. *J Heart Lung Transplant* 2017;36:940-7.
76. Correia P, Prieto D, Batista M, Antunes MJ. Gender mismatch between donor and recipient is a factor of morbidity but does not condition survival after cardiac transplantation. *Transpl Int* 2014;27:1303-10.
77. Fonarow GC. How old is too old for heart transplantation? *Curr Opin Cardiol* 2000;15:97-103.
78. Everett JE, Djalilian AR, Kubo SH, Kroschus TJ, Shumway SJ. Heart transplantation for patients over age 60. *Clin Transplant* 1996;10(6 Pt 1):478-81.
79. Gong TA, Joseph SM, Lima B, et al. Donor predicted heart mass as predictor of primary graft dysfunction. *J Heart Lung Transplant* 2018;37:826-35.
80. O'Neill TJ, Pisani B. Size matching in heart transplantation donor selection: "Too big to fail"? *J Heart Lung Transplant* 2017;36:934-5.
81. Jasseron C, Legeai C, Jacquelinet C, et al. Optimization of heart allocation: the transplant risk score. *Am J Transplant* 2019;19:1507-17.
82. Russo MJ, Iribarne A, Hong KN, et al. Factors associated with primary graft failure after heart transplantation. *Transplantation* 2010;90:444-50.
83. Madan S, Patel SR, Vlismas P, et al. Outcomes of early adolescent donor hearts in adult transplant recipients. *JACC Heart Fail* 2017;5:879-87.
84. Stehlik J, Islam N, Hurst D, et al. Utility of virtual crossmatch in sensitized patients awaiting heart transplantation. *J Heart Lung Transplant* 2009;28:1129-34.
85. Jawitz OK, GJ N, Yuh DD, Bonde P. Impact of ABO compatibility on outcomes after heart transplantation in a national cohort during the past decade. *J Thorac Cardiovasc Surg* 2013;146:1239-45. discussion 1245-1236.
86. Neves C, Prieto D, Sola E, Antunes MJ. Heart transplantation from donors of different ABO blood type. *Transplant Proc* 2009;41:938-40.
87. Foreman C, Gruenwald C, West L. ABO-incompatible heart transplantation: a perfusion strategy. *Perfusion* 2004;19:69-72.
88. Pflugfelder PW, Singh NR, McKenzie FN, Menkis AH, Novick RJ, Kostuk WJ. Extending cardiac allograft ischemic time and donor age: effect on survival and long-term cardiac function. *J Heart Lung Transplant* 1991;10:394-400.
89. Charniot JC, Bonnefont-Rousselot D, Albertini JP, et al. Oxidative stress implication after prolonged storage donor heart with blood versus crystalloid cardioplegia and reperfusion versus static storage. *J Surg Res* 2010;160:308-14.
90. Marasco SF, Esmore DS, Negri J, et al. Early institution of mechanical support improves outcomes in primary cardiac allograft failure. *J Heart Lung Transplant* 2005;24:2037-42.
91. Russo MJ, Chen JM, Sorabella RA, et al. The effect of ischemic time on survival after heart transplantation varies by donor age: an analysis of the United Network for Organ Sharing database. *J Thorac Cardiovasc Surg* 2007;133:554-9.
92. Hong KN, Iribarne A, Worku B, et al. Who is the high-risk recipient? Predicting mortality after heart transplant using pretransplant donor and recipient risk factors. *Ann Thorac Surg* 2011;92:520-7.
93. González-Vilchez F, Almenar-Bonet L, Crespo-Leiro MG, et al. Spanish Heart Transplant Registry. 29th official report of the Spanish Society of Cardiology working group on heart failure. *Rev Esp Cardiol (Engl Ed)* 2018;71:952-60.
94. Reich HJ, Kobashigawa JA, Aintablian T, Ramzy D, Kittleson MM, Esmailian F. Effects of older donor age and cold ischemic time on long-term outcomes of heart transplantation. *Tex Heart Inst J* 2018;45:17-22.
95. Gaffey AC, Chen CW, Chung JJ, et al. Extended distance cardiac allograft can successfully be utilized without impacting long-term survival. *J Heart Lung Transplant* 2017;36:968-72.
96. Kur F, Beiras-Fernandez A, Meiser B, Uberfuhr P, Reichart B. Clinical heart transplantation with extended preservation time (>5 hours): experience with University of Wisconsin solution. *Transplant Proc* 2009;41:2247-9.
97. Mitropoulos FA, Odum J, Marelli D, et al. Outcome of hearts with cold ischemic time greater than 300 minutes. A case-matched study. *Eur J Cardiothorac Surg* 2005;28:143-8.
98. Morgan JA, John R, Weinberg AD, et al. Prolonged donor ischemic time does not adversely affect long-term survival in adult patients undergoing cardiac transplantation. *J Thorac Cardiovasc Surg* 2003;126:1624-33.
99. Yeen W, Polgar A, Guglin M, et al. Outcomes of adult orthotopic heart transplantation with extended allograft ischemic time. *Transplant Proc* 2013;45:2399-405.
100. Banner NR, Thomas HL, Curnow E, Hussey JC, Rogers CA, Bonser RS. The importance of cold and warm cardiac ischemia for survival after heart transplantation. *Transplantation* 2008;86:542-7.
101. Conway J, Chin C, Kemna M, et al. Donors' characteristics and impact on outcomes in pediatric heart transplant recipients. *Pediatr Transplant* 2013;17:774-81.
102. Ford MA, Almond CS, Gauvreau K, et al. Association of graft ischemic time with survival after heart transplant among children in the United States. *J Heart Lung Transplant* 2011;30:1244-9.
103. Haneya A, Haake N, Diez C, et al. Impact of the Eurotransplant high-urgency heart allocation system on the outcome of transplant candidates in Germany. *Thorac Cardiovasc Surg* 2011;59:93-7.
104. Goff RR, Uccellini K, Lindblad K, et al. A change of heart: preliminary results of the US 2018 adult heart allocation revision. *Am J Transplant* 2020;20:2781-90.
105. Segovia J, Cosio MD, Barcelo JM, et al. RADIAL: a novel primary graft failure risk score in heart transplantation. *J Heart Lung Transplant* 2011;30:644-51.
106. Wever Pinzon O, Stoddard G, Drakos SG, et al. Impact of donor left ventricular hypertrophy on survival after heart transplant. *Am J Transplant* 2011;11:2755-61.
107. García Sáez D, Zych B, Sabashnikov A, et al. Evaluation of the organ care system in heart transplantation with an adverse donor/recipient profile. *Ann Thorac Surg* 2014;98:2099-105. discussion 2105-2096.
108. Ardehali A, Esmailian F, Deng M, et al. Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective,

- open-label, multicentre, randomised non-inferiority trial. *Lancet* 2015;385:2577-84.
109. Kalyev R, Bekbosynov S, Nurmykhametova Z. Sixteen-hour ex vivo donor heart perfusion during long-distance transportation for heart transplantation. *Artif Organs* 2019;43:319-20.
 110. Goland S, Czer LS, Kass RM, et al. Use of cardiac allografts with mild and moderate left ventricular hypertrophy can be safely used in heart transplantation to expand the donor pool. *J Am Coll Cardiol* 2008;51:1214-20.
 111. Marelli D, Laks H, Fazio D, Moore S, Moriguchi J, Kobashigawa J. The use of donor hearts with left ventricular hypertrophy. *J Heart Lung Transplant* 2000;19:496-503.
 112. Ferrera R, Hadour G, Tamion F, et al. Brain death provokes very acute alteration in myocardial morphology detected by echocardiography: Preventive effect of beta-blockers. *Transpl Int* 2011;24:300-6.
 113. Kuppalaly SS, Valantine HA, Weisshaar D, et al. Outcome in cardiac recipients of donor hearts with increased left ventricular wall thickness. *Am J Transplant* 2007;7:2388-95.
 114. Aziz S, Soine LA, Lewis SL, et al. Donor left ventricular hypertrophy increases risk for early graft failure. *Transpl Int* 1997;10:446-50.
 115. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. *Eur J Echocardiogr* 2006;7:79-108.
 116. Eurotransplant. Annual report. 2017; <http://www.eurotransplant.org/wp-content/uploads/2019/12/Annual-Report-2017-HR.pdf>.
 117. Khush KK, Menza R, Nguyen J, Zaroff JG, Goldstein BA. Donor predictors of allograft use and recipient outcomes after heart transplantation. *Circ Heart Fail* 2013;6:300-9.
 118. Gao HZ, Hunt SA, Alderman EL, Liang D, Yeung AC, Schroeder JS. Relation of donor age and preexisting coronary artery disease on angiography and intracoronary ultrasound to later development of accelerated allograft coronary artery disease. *J Am Coll Cardiol* 1997;29:623-9.
 119. Yamasaki M, Sakurai R, Hirohata A, et al. Impact of donor-transmitted atherosclerosis on early cardiac allograft vasculopathy: new findings by three-dimensional intravascular ultrasound analysis. *Transplantation* 2011;91:1406-11.
 120. Grauhan O, Siniawski H, Dandel M, et al. Coronary atherosclerosis of the donor heart—impact on early graft failure. *Eur J Cardiothorac Surg* 2007;32:634-8.
 121. Deng MC, De Meester JM, Smits JM, Heinecke J, Scheld HH. Effect of receiving a heart transplant: Analysis of a national cohort entered on to a waiting list, stratified by heart failure severity. Comparative Outcome and Clinical Profiles in Transplantation (COCPIT) Study Group. *Bmj* 2000;321:540-5.
 122. Lechiancole A, Vendramin I, Sponga S, et al. Influence of donor-transmitted coronary artery disease on long-term outcomes after heart transplantation - a retrospective study. *Transpl Int* 2021;34:281-9.
 123. Ivanov F, Cantrelle C, Genet T, et al. Performing diagnostic coronary angiography to evaluate high-risk cardiac donors: a French nationwide cohort study. *Int J Cardiol* 2019;277:71-8.
 124. Grosse K, Brauer B, Küçük O, et al. Does contrast medium administration in organ donors affect early kidney graft function? *Transplant Proc* 2006;38:668-9.
 125. Baldwin JC, Anderson JL, Boucek MM, et al. 24th Bethesda conference: cardiac transplantation. Task Force 2: donor guidelines. *J Am Coll Cardiol* 1993;22:15-20.
 126. Organ OPTN/UNOS. Procurement Organization Committee. Guidance on requested deceased donor information; 2018. https://optn.transplant.hrsa.gov/media/2528/opo_boardreport_201806_guidance.pdf.
 127. European Directorate for the Quality of Medicines and Healthcare. Guide to the Quality and Safety of Organs for Transplantation. 8th edition. Strassbourg, France: Council of Europe; 2022 <https://www.edqm.eu/guide-quality-and-safety-organs-transplantation>. Accessed November 4, 2022.
 128. Taghavi S, Jayarajan SN, Wilson LM, Komaroff E, Testani JM, Mangi AA. Cardiac transplantation can be safely performed using selected diabetic donors. *J Thorac Cardiovasc Surg* 2013;146:442-7.
 129. Khush KK, Potena L, Cherikh WS, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult heart transplantation report-2020; focus on deceased donor characteristics. *J Heart Lung Transplant* 2020;39:1003-15.
 130. Kilic A, Weiss ES, George TJ, et al. What predicts long-term survival after heart transplantation? An analysis of 9,400 ten-year survivors. *Ann Thorac Surg* 2012;93:699-704.
 131. Joseph JT, Mulvihill MS, Yerokun BA, Bell SM, Milano CA, Hartwig MG. Elevated donor hemoglobin A1c does not impair early survival in cardiac transplant recipients [e-pub ahead of print]. *Clin Transplant* 2017;31. <https://doi.org/10.1111/ctr.12995>.
 132. Cheng A, Schumer EM, Trivedi JR, Van Berkel VH, Massey HT, Slaughter MS. Does donor cardiopulmonary resuscitation time affect heart transplantation outcomes and survival? *Ann Thorac Surg* 2016;102:751-8.
 133. Galeone A, Lebreton G, Leprince P. Old Europe carefully looks at a new heart: cardiac arrest-resuscitated donors should not be turned down for heart transplant at first glance. *J Thorac Cardiovasc Surg* 2017;154:540.
 134. Quader MA, Wolfe LG, Kasirajan V. Heart transplantation outcomes from cardiac arrest-resuscitated donors. *J Heart Lung Transplant* 2013;32:1090-5.
 135. Quader M, Wolfe L, Katlaps G, Kasirajan V. Donor heart utilization following cardiopulmonary arrest and resuscitation: influence of donor characteristics and wait times in transplant regions. *J Transplant* 2014;2014:519401.
 136. Southerland KW, Castleberry AW, Williams JB, Daneshmand MA, Ali AA, Milano CA. Impact of donor cardiac arrest on heart transplantation. *Surgery* 2013;154:312-9.
 137. L'Ecuyer T, Sloan K, Tang L. Impact of donor cardiopulmonary resuscitation on pediatric heart transplant outcome. *Pediatr Transplant* 2011;15:742-5.
 138. Dark JH, Mehew J, Venkateswaran R. Prolongation of time from brain death to retrieval is beneficial to the donor heart. *J Thorac Cardiovasc Surg* 2021;161:e311-2.
 139. Fagerström K. The epidemiology of smoking: health consequences and benefits of cessation. *Drugs* 2002;62(Suppl 2):1-9.
 140. Shea KJ, Sopko NA, Ludrosky K, et al. The effect of a donor's history of active substance on outcomes following orthotopic heart transplantation. *Eur J Cardiothorac Surg* 2007;31:452-6. discussion 456.
 141. Kim MS, Kang SJ, Lee CW, et al. Prevalence of coronary atherosclerosis in asymptomatic healthy subjects: an intravascular ultrasound study of donor hearts. *J Atheroscler Thromb* 2013;20:465-71.
 142. Tsao CI, Chen RJ, Chou NK, et al. The influence of donor characteristics on survival after heart transplantation. *Transplant Proc* 2008;40:2636-7.
 143. Rizzi G, Startseva X, Wolfrum M, et al. Unfavorable donor pretransplant APACHE II, SAPS II, and SOFA scores are not associated with outcome: implications for heart transplant donor selection. *Transplant Proc* 2016;48:2582-7.
 144. El Oakley RM, Yonan NA, Simpson BM, Deiraniya AK. Extended criteria for cardiac allograft donors: a consensus study. *J Heart Lung Transplant* 1996;15:255-9.
 145. Bollinger O. Über die Häufigkeit und Ursachen der idiopathischen Herzhypertrophie in München. *Deu Med Wochenschr* 1884;10:180-1.
 146. Wang S, Ren J. Role of autophagy and regulatory mechanisms in alcoholic cardiomyopathy. *Biochim Biophys Acta Mol Basis Dis* 2018;1864(6 Pt A):2003-9.
 147. Houyel L, Petit J, Nottin R, Duffet JP, Macé L, Neveux JY. Adult heart transplantation: Adverse role of chronic alcoholism in donors on early graft function. *J Heart Lung Transplant* 1992;11:1184-7.
 148. Freimark D, Aleksic I, Trento A, et al. Hearts from donors with chronic alcohol use: a possible risk factor for death after heart transplantation. *J Heart Lung Transplant* 1996;15:150-9.
 149. Taghavi S, Jayarajan SN, Komaroff E, et al. Use of heavy drinking donors in heart transplantation is not associated with worse mortality. *Transplantation* 2015;99:1226-30.

150. De La Zerda DJ, Cohen O, Beygui RE, Kobashigawa J, Hekmat D, Laks H. Alcohol use in donors is a protective factor on recipients' outcome after heart transplantation. *Transplantation* 2007;83:1214-8.
151. Newman J, Liebo M, Lowes BD, et al. The effect of donor alcohol abuse on outcomes following heart transplantation. *Clin Transplant* 2019;33:e13461.
152. Peled Y, Varnado S, Lowes BD, et al. Sinus tachycardia is associated with impaired exercise tolerance following heart transplantation [e-pub ahead of print]. *Clin Transplant* 2017;31. <https://doi.org/10.1111/ctr.12946>.
153. Wood DM, Dargan PI, Jones AL. Poisoned patients as potential organ donors: postal survey of transplant centres and intensive care units. *Crit Care* 2003;7:147-54.
154. Warraich HJ, Lu D, Cobb S, et al. Trends and outcomes of cardiac transplantation from donors dying of drug intoxication. *Am Heart J* 2018;199:92-6.
155. Jayarajan S, Taghavi S, Komaroff E, et al. Long-term outcomes in heart transplantation using donors with a history of past and present cocaine use. *Eur J Cardiothorac Surg* 2015;47:e146-50.
156. Briek A, Krishnamani R, Rocha MJ, et al. Influence of donor cocaine use on outcome after cardiac transplantation: analysis of the United Network for Organ Sharing Thoracic Registry. *J Heart Lung Transplant* 2008;27:1350-2.
157. Baran D, Long A, Lansinger J, et al. What are you smoking? The impact of donor drug use on long term survival post-transplant [Abstract]. *Am J Transpl* 2019;19(Suppl 3). Available at: <https://atc-meetingabstracts.com/abstract/what-are-you-smoking-the-impact-of-donor-drug-use-on-long-term-survival-post-transplant/>.
158. Lansinger JT, Long A, Barreiro C, et al. Donors and Drugs: How Often Do They Mix? Utilization of Donors Based on Toxicology Findings [e-pub ahead of print]. *Am J Transplant* 2019;19(Suppl 3). <https://doi.org/10.1161/CIRCHEARTFAILURE.122.009547>.
159. Vieira JL, Cherikh WS, Lindblad K, Stehlik J, Mehra MR. Cocaine use in organ donors and long-term outcome after heart transplantation: an International Society for Heart and Lung Transplantation registry analysis. *J Heart Lung Transplant* 2020;39:1341-50.
160. Baran DA, Lansinger J, Long A, et al. Intoxicated donors and heart transplant outcomes: long-term safety. *Circ Heart Fail* 2021;14:e007433.
161. Fishman JA, Greenwald MA, Grossi PA. Transmission of infection with human allografts: essential considerations in donor screening. *Clin Infect Dis* 2012;55:720-7.
162. Len O, Los-Arcos I, Aguado JM, et al. Selection criteria of solid organ donors in relation to infectious diseases: a Spanish consensus. *Transplant Rev (Orlando)* 2020;34:100528.
163. Ison MG, Nalesnik MA. An update on donor-derived disease transmission in organ transplantation. *Am J Transplant* 2011;11:1123-30.
164. Wolfe CR, Ison MG. Donor-derived infections: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant* 2019;33:e13547.
165. Kubak BM, Gregson AL, Pegues DA, et al. Use of hearts transplanted from donors with severe sepsis and infectious deaths. *J Heart Lung Transplant* 2009;28:260-5.
166. Singh N, Huprikar S, Burdette SD, Morris MI, Blair JE, Wheat LJ. Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, Infectious Diseases Community of Practice. *Am J Transplant* 2012;12:2414-28.
167. Sun HY, Alexander BD, Lortholary O, et al. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients. *Clin Infect Dis* 2010;51:1062-9.
168. Gomez CA, Singh N. Donor-derived filamentous fungal infections in solid organ transplant recipients. *Curr Opin Infect Dis* 2013;26:309-16.
169. Gajurel K, Dhakal R, Deresinski S. Histoplasmosis in transplant recipients [e-pub ahead of print]. *Clin Transplant* 2017;31. <https://doi.org/10.1111/ctr.13087>.
170. Nelson JK, Giraldeau G, Montoya JG, Deresinski S, Ho DY, Pham M. Donor-Derived *Coccidioides immitis* Endocarditis and Disseminated Infection in the Setting of Solid Organ Transplantation [e-pub ahead of print]. *Open Forum Infect Dis* 2016;3. <https://doi.org/10.1093/ofid/ofw086>.
171. Cuellar-Rodriguez J, Avery RK, Lard M, et al. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. *Clin Infect Dis* 2009;49:710-6.
172. Kusne S, Taranto S, Covington S, et al. *Coccidioidomycosis* transmission through organ transplantation: a report of the OPTN Ad Hoc disease transmission advisory committee. *Am J Transplant* 2016;16:3562-7.
173. Kovacs CS, Koval CE, van Duin D, et al. Selecting suitable solid organ transplant donors: reducing the risk of donor-transmitted infections. *World J Transplant* 2014;4:43-56.
174. Blanes M, Gomez D, Cordoba J, et al. Is there any risk of transmission of hepatitis B from heart donors hepatitis B core antibody positive? *Transplant Proc* 2002;34:61-2.
175. Chamorro C, Aparicio M. Influence of HBcAb positivity in the organ donor in heart transplantation. *Med Intensiva* 2012;36:563-70.
176. Chen YC, Chuang MK, Chou NK, et al. Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation. *Transplant Proc* 2012;44:910-2.
177. De Feo TM, Poli F, Mozzi F, Moretti MP, Scalapogna M. Risk of transmission of hepatitis B virus from anti-HBc positive cadaveric organ donors: a collaborative study. *Transplant Proc* 2005;37:1238-9.
178. Dhillon GS, Levitt J, Mallidi H, et al. Impact of hepatitis B core antibody positive donors in lung and heart-lung transplantation: an analysis of the United Network for organ sharing database. *Transplantation* 2009;88:842-6.
179. Horan JL, Stout JE, BD Alexander. Hepatitis B core antibody-positive donors in cardiac transplantation: a single-center experience. *Transpl Infect Dis* 2014;16:859-63.
180. Huprikar S, Danziger-Isakov L, Ahn J, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. *Am J Transplant* 2015;15:1162-72.
181. Krassilnikova M, Deschenes M, Techevnikov J, Giannetti N, Cecere R, Cantarovich M. Effectiveness of post-transplant prophylaxis with anti-hepatitis B virus immunoglobulin in recipients of heart transplant from hepatitis B virus core antibody positive donors. *Transplantation* 2007;83:1523-4.
182. Large SR. Impact of hepatitis B core antibody positive donors in lung and heart-lung transplantation: an analysis of the UNOS database. *Transplantation* 2009;88:759.
183. Organ Procurement and Transplantation Network. Policy 1: Administrative rules and definitions. 2021; https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf.
184. Pinney SP, Cheema FH, Hammond K, Chen JM, Edwards NM, Mancini D. Acceptable recipient outcomes with the use of hearts from donors with hepatitis-B core antibodies. *J Heart Lung Transplant* 2005;24:34-7.
185. Salvadori M, Rosso G, Carta P, Larti A, di Maria L, Bertoni E. Donors positive for hepatitis B core antibodies in nonliver transplantations. *Transplant Proc* 2011;43:277-9.
186. Shin HS, Cho HJ, Jeon ES, et al. The impact of hepatitis B on heart transplantation: 19 years of national experience in Korea. *Ann Transplant* 2014;19:182-7.
187. Tenderich G, Zittermann A, Prohaska W, et al. Frequent detection of hepatitis B core antibodies in heart transplant recipients without preceding hepatitis B infection. *Transplant Proc* 2005;37:4522-4.
188. Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. *Transplantation* 1995;59:230-4.
189. Aslam S, Grossi P, Schlendorf KH, et al. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: an ISHLT expert consensus statement. *J Heart Lung Transplant* 2020;39:418-32.
190. Blumberg EA. Organs from hepatitis C virus-positive donors. *N Engl J Med* 2019;380:1669-70.
191. Gasink LB, Blumberg EA, Localio AR, Desai SS, Israni AK, Lautenbach E. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. *Jama* 2006;296:1843-50.
192. Gidea CG, Narula N, Reyentovich A, et al. Increased early acute cellular rejection events in hepatitis C-positive heart transplantation. *J Heart Lung Transplant* 2020;39:1199-207.

193. Gottlieb RL, Hall SA. The new direct antiviral agents and hepatitis C in thoracic transplantation: impact on donors and recipients. *Curr Transplant Rep* 2018;5:145-52.
194. McLean RC, Reese PP, Acker M, et al. Transplanting hepatitis C virus-infected hearts into uninfected recipients: a single-arm trial. *Am J Transplant* 2019;19:2533-42.
195. Patel SR, Madan S, Saeed O, et al. Cardiac transplantation from non-viremic hepatitis C donors. *J Heart Lung Transplant* 2018;37:1254-60.
196. Schlendorf KH, Zalawadiya S, Shah AS, et al. Early outcomes using hepatitis c-positive donors for cardiac transplantation in the era of effective direct-acting antiviral therapies. *J Heart Lung Transplant* 2018;37:763-9.
197. Woolley AE, Singh SK. The curious phenomenon of early cardiac allograft rejection with hepatitis C-infected donor heart transplants. *J Heart Lung Transplant* 2020;39:1208-9.
198. Woolley AE, Singh SK, Goldberg HJ, et al. Heart and lung transplants from HCV-infected donors to uninfected recipients. *N Engl J Med* 2019;380:1606-17.
199. Boyarsky BJ, Durand CM, Palella FJ, Segev DL. Challenges and clinical decision-making in HIV-to-HIV transplantation: insights from the HIV literature. *Am J Transplant* 2015;15:2023-30.
200. Chen C, Wen X, Yadav A, Belviso N, Kogut S, McCauley J. Outcomes in human immunodeficiency virus-infected recipients of heart transplants. *Clin Transplant* 2019;33:e13440.
201. Madan S, Patel SR, Saeed O, et al. Outcomes of heart transplantation in patients with human immunodeficiency virus. *Am J Transplant* 2019;19:1529-35.
202. Miro JM, Grossi PA, Durand CM. Challenges in solid organ transplantation in people living with HIV. *Intensive Care Med* 2019;45:398-400.
203. Muller E, Barday Z, Mendelson M, Kahn D. HIV-positive-to-HIV-positive kidney transplantation—results at 3 to 5 years. *N Engl J Med* 2015;372:613-20.
204. National Institutes of Health. Final Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV. Washington, DC: National Archives; 2015. (80 FR 73785) <https://www.federalregister.gov/documents/2015/11/25/2015-30172/final-human-immunodeficiency-virus-hiv-organ-policy-equity-hope-act-safeguards-and-research-criteria>. Accessed July 25, 2021.
205. Organ Procurement and Transplantation Network. Modify HOPE Act Variance to Include Other. Organs 2019 https://optn.transplant.hrsa.gov/media/2800/dtac_publiccomment_20190122.pdf.
206. Selhorst P, Combrinck CE, Manning K, et al. Longer-term outcomes of HIV-positive-to-HIV-positive renal transplantation. *N Engl J Med* 2019;381:1387-9.
207. Uriel N, Jorde UP, Cotarlan V, et al. Heart transplantation in human immunodeficiency virus-positive patients. *J Heart Lung Transplant* 2009;28:667-9.
208. Malinis M, Koff A. Mycobacterium tuberculosis in solid organ transplant donors and recipients. *Curr Opin Organ Transplant* 2021;26:432-9.
209. Bixler D, Annambholta P, Abara WE, et al. Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014-2017. *Am J Transplant* 2019;19:2570-82.
210. Gaffey AC, Doll SL, Thomasson AM, et al. Transplantation of "high-risk" donor hearts: implications for infection. *J Thorac Cardiovasc Surg* 2016;152:213-20.
211. Green M, Covington S, Taranto S, et al. Donor-derived transmission events in 2013: a report of the organ procurement transplant network ad hoc disease transmission advisory committee. *Transplantation* 2015;99:282-7.
212. Grossi PA, Dalla Gasperina D, Lombardi D, Ricci A, Piccolo G, Nanni Costa A. Organ transplantation from "increased infectious risk donors": the experience of the Nord Italia Transplant program - a retrospective study. *Transpl Int* 2018;31:212-9.
213. Humar A, Morris M, Blumberg E, et al. Nucleic acid testing (NAT) of organ donors: is the 'best' test the right test? A consensus conference report. *Am J Transplant* 2010;10:889-99.
214. Irwin L, Kotton CN, Elias N, et al. Utilization of increased risk for transmission of infectious disease donor organs in solid organ transplantation: retrospective analysis of disease transmission and safety. *Transpl Infect Dis* 2017;19.
215. Ison MG, Llata E, Conover CS, et al. Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients. *Am J Transplant* 2011;11:1218-25.
216. Jones JM, Gurbaxani BM, Asher A, et al. Quantifying the risk of undetected HIV, hepatitis B virus, or hepatitis C virus infection in public health service increased risk donors. *Am J Transplant* 2019;19:2583-93.
217. Jones JM, Kracalik I, Levi ME, et al. Assessing solid organ donors and monitoring transplant recipients for human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection - U.S. public health service guideline, 2020. *MMWR Recomm Rep* 2020;69:1-16.
218. Kaul DR, Tlusty SM, Michaels MG, Limaye AP, Wolfe CR. Donor-derived hepatitis C in the era of increasing intravenous drug use: a report of the disease transmission advisory committee. *Clin Transplant* 2018;32:e13370.
219. Kucirka LM, Sarathy H, Govindan P, et al. Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis. *Am J Transplant* 2011;11:1188-200.
220. Kucirka LM, Sarathy H, Govindan P, et al. Risk of window period HIV infection in high infectious risk donors: systematic review and meta-analysis. *Am J Transplant* 2011;11:1176-87.
221. Organ Procurement and Transplantation Network. Policy 15: Identification of transmissible diseases. 2021; https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf.
222. Organ Procurement and Transplantation Network. Policy 2.9: Required deceased donor infectious disease testing. https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf.
223. Sahulee R, Lytrivi ID, Savla JJ, Rossano JW. Centers for disease control "high-risk" donor status does not significantly affect recipient outcome after heart transplantation in children. *J Heart Lung Transplant* 2014;33:1173-7.
224. Shudo Y, Cohen JE, Lingala B, He H, Zhu Y, Woo YJ. Impact of "increased-risk" donor hearts on transplant outcomes: a propensity-matched analysis. *J Thorac Cardiovasc Surg* 2019;157:603-10.
225. Suryaprasad A, Basavaraju SV, Hoccovar SN, et al. Transmission of hepatitis C virus from organ donors despite nucleic acid test screening. *Am J Transplant* 2015;15:1827-35.
226. White SL, Rawlinson W, Boan P, et al. Infectious disease transmission in solid organ transplantation: donor evaluation, recipient risk, and outcomes of transmission. *Transplant Direct* 2019;5:e416.
227. Aslam S, Goldstein DR, Vos R, et al. COVID-19 vaccination in our transplant recipients: the time is now. *J Heart Lung Transplant* 2021;40:169-71.
228. Aslam S, Mehra MR. COVID-19: yet another coronavirus challenge in transplantation. *J Heart Lung Transplant* 2020;39:408-9.
229. Bragin-Sánchez D, Chang PP. West Nile virus encephalitis infection in a heart transplant recipient: a case report. *J Heart Lung Transplant* 2005;24:621-3.
230. Holm AM, Mehra MR, Courtwright A, et al. Ethical considerations regarding heart and lung transplantation and mechanical circulatory support during the COVID-19 pandemic: an ISHLT COVID-19 Task Force statement. *J Heart Lung Transplant* 2020;39:619-26.
231. Iacovoni A, Boffini M, Pidello S, et al. A case series of novel coronavirus infection in heart transplantation from 2 centers in the pandemic area in the North of Italy. *J Heart Lung Transplant* 2020;39:1081-8.
232. Iwamoto M, Jernigan DB, Guasch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. *N Engl J Med* 2003;348:2196-203.
233. Kates OS, Haydel BM, Florman SS, et al. COVID-19 in solid organ transplant: a multi-center cohort study. *Clin Infect Dis* 2020;73:e4090-9.
234. Kaul DR, Valesano AL, Petrie JG, et al. Donor to recipient transmission of SARS-CoV-2 by lung transplantation despite negative donor upper respiratory tract testing. *Am J Transplant* 2021;21:2885-9.

235. Kotton CN. Zika virus and solid organ transplantation: significant pathogen or harbinger of things to come? *Transplantation* 2016;100:970-2.
236. Levi ME. Zika virus: a cause of concern in transplantation? *Curr Opin Infect Dis* 2017;30:340-5.
237. Li F, Cai J, Dong N. First cases of COVID-19 in heart transplantation from China. *J Heart Lung Transplant* 2020;39:496-7.
238. Nogueira ML, Estofolete CF, Terzian AC, et al. Zika virus infection and solid organ transplantation: a new challenge. *Am J Transplant* 2017;17:791-5.
239. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. *Am J Transplant* 2020;20:1800-8.
240. Rosen A, Ison MG. Screening of living organ donors for endemic infections: understanding the challenges and benefits of enhanced screening. *Transpl Infect Dis* 2017;19:e12633.
241. Schwartzmann PV, Ramalho LN, Neder L, et al. Zika virus meningoencephalitis in an immunocompromised patient. *Mayo Clin Proc* 2017;92:460-6.
242. Silveira FP, Campos SV. The Zika epidemics and transplantation. *J Heart Lung Transplant* 2016;35:560-3.
243. Winston DJ, Vikram HR, Rabe IB, et al. Donor-derived West Nile virus infection in solid organ transplant recipients: report of four additional cases and review of clinical, diagnostic, and therapeutic features. *Transplantation* 2014;97:881-9.
244. Benvenuti LA, Rogério A, Cavalcanti MM, Nishiya AS, Levi JE. An autopsy-based study of *Trypanosoma cruzi* persistence in organs of chronic chagasic patients and its relevance for transplantation. *Transpl Infect Dis* 2017;19.
245. Casadei D. Chagas' disease and solid organ transplantation. *Transplant Proc* 2010;42:3354-9.
246. Chin-Hong PV, Schwartz BS, Bern C, et al. Screening and treatment of chagas disease in organ transplant recipients in the United States: recommendations from the chagas in transplant working group. *Am J Transplant* 2011;11:672-80.
247. Kim JH, Kim DS, Yoon YK, Sohn JW, Kim MJ. Donor-derived Strongyloidiasis infection in solid organ transplant recipients: a review and pooled analysis. *Transplant Proc* 2016;48:2442-9.
248. Kun H, Moore A, Mascola L, et al. Transmission of *Trypanosoma cruzi* by heart transplantation. *Clin Infect Dis* 2009;48:1534-40.
249. Le M, Ravin K, Hasan A, et al. Single donor-derived strongyloidiasis in three solid organ transplant recipients: case series and review of the literature. *Am J Transplant* 2014;14:1199-206.
250. Pinazo MJ, Miranda B, Rodríguez-Villar C, et al. Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas. *Transplant Rev (Orlando)* 2011;25:91-101.
251. Sadjadi SA, Damodaran C, Sharif M. Strongyloides stercoralis infection in transplanted patients. *Am J Case Rep* 2013;14:205-9.
252. Schwartz BS, Mawhorter SD. Parasitic infections in solid organ transplantation. *Am J Transplant* 2013;13(Suppl 4):280-303.
253. Kaul DR, Covington S, Taranto S, et al. Solid organ transplant donors with central nervous system infection. *Transplantation* 2014;98:666-70.
254. Organ Procurement and Transplantation Network. Guidance for Recognizing Central Nervous System Infections in Potential Deceased Organ Donors. 2014; <https://optn.transplant.hrsa.gov/resources/guidance/guidance-for-recognizing-central-nervous-system-infections-in-potential-deceased-organ-donors/>.
255. Buell JF, Trofe J, Hanaway MJ, et al. Transmission of donor cancer into cardiothoracic transplant recipients. *Surgery* 2001;130:660-6. discussion 666-668.
256. Desai R, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J. Cancer transmission from organ donors-unavoidable but low risk. *Transplantation* 2012;94:1200-7.
257. Garrido G, Matesanz R. The Spanish National Transplant Organization (ONT) tumor registry. *Transplantation* 2008;85(8 Suppl):S61-3.
258. Hornik L, Tenderich G, Wlost S, Zittermann A, Minami K, Koerfer R. Organs from donors with primary brain malignancy: the fate of cardiac allograft recipients. *Transplant Proc* 2004;36:3133-7.
259. Huang S, Tang Y, Zhu Z, et al. Outcomes of organ transplantation from donors with a cancer history. *Med Sci Monit* 2018;24:997-1007.
260. Kauffman HM, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. *Transplantation* 2002;74:358-62.
261. Zucchini N, Fiorentino M, D'Errico Grigioni A, et al. The Italian multiorgan donor cancer screening protocol: 2002-2005 experience. *Transplantation* 2008;85(8 Suppl):S57-60.
262. Nalesnik MA, Woodle ES, Dimaio JM, et al. Donor-transmitted malignancies in organ transplantation: assessment of clinical risk. *Am J Transplant* 2011;11:1140-7.
263. Tomida M, Muraki M, Uemura K, Yamasaki K. Plasma concentrations of brain natriuretic peptide in patients with subarachnoid hemorrhage. *Stroke* 1998;29:1584-7.
264. Tung PP, Olmsted E, Kopelnik A, et al. Plasma B-type natriuretic peptide levels are associated with early cardiac dysfunction after subarachnoid hemorrhage. *Stroke* 2005;36:1567-9.
265. Anderson JR, Hossein-Nia M, Brown P, Holt DW, Murday A. Donor cardiac troponin-T predicts subsequent inotrope requirements following cardiac transplantation. *Transplantation* 1994;58:1056-7.
266. Potapov EV, Ivanitskaia EA, Loebe M, et al. Value of cardiac troponin I and T for selection of heart donors and as predictors of early graft failure. *Transplantation* 2001;71:1394-400.
267. Freundt M, Philipp A, Kolat P, et al. Impact of elevated donor troponin I as predictor of adverse outcome in adult heart transplantation: a single-center experience. *Thorac Cardiovasc Surg* 2018;66:417-24.
268. Madan S, Saeed O, Shin J, et al. Donor troponin and survival after cardiac transplantation: an analysis of the united network of organ sharing registry. *Circ Heart Fail* 2016;9:e002909. <https://doi.org/10.1161/CIRCHEARTFAILURE.115.002909>.
269. Dronavalli VB, Banner NR, Bonser RS. Assessment of the potential heart donor: a role for biomarkers? *J Am Coll Cardiol* 2010;56:352-61.
270. Vorlat A, Conraads VM, Jorens PG, et al. Donor B-type natriuretic peptide predicts early cardiac performance after heart transplantation. *J Heart Lung Transplant* 2012;31:579-84.
271. Bombardini T, Arpesella G, Maccherini M, et al. Medium-term outcome of recipients of marginal donor hearts selected with new stress-echocardiographic techniques over standard criteria. *Cardiovasc Ultrasound* 2014;12:20.
272. Bombardini T, Gherardi S, Arpesella G, et al. Favorable short-term outcome of transplanted hearts selected from marginal donors by pharmacological stress echocardiography. *J Am Soc Echocardiogr* 2011;24:353-62.
273. Bombardini T, Gherardi S, Leone O, Sicari R, Picano E. Transplant of stunned donor hearts rescued by pharmacological stress echocardiography: a "proof of concept" report. *Cardiovasc Ultrasound* 2013;11:27.
274. Borbely XI, Krishnamoorthy V, Modi S, et al. Temporal changes in left ventricular systolic function and use of echocardiography in adult heart donors. *Neurocrit Care* 2015;23:66-71.
275. Casartelli M, Bombardini T, Simion D, Gaspari MG, Procaccio F. Wait, treat and see: echocardiographic monitoring of brain-dead potential donors with stunned heart. *Cardiovasc Ultrasound* 2012;10:25.
276. Dorosz JL, Lezotte DC, Weitzkamp DA, Allen LA, Salcedo EE. Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis. *J Am Coll Cardiol* 2012;59:1799-808.
277. Khush KK, Nguyen J, Goldstein BA, McGlothlin DP, Zaroff JG. Reliability of transthoracic echocardiogram interpretation in potential adult heart transplant donors. *J Heart Lung Transplant* 2015;34:266-9.
278. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2015;28:1-39. e14.
279. Nair N, Gongora E. Role of cardiovascular imaging in selection of donor hearts. *World J Transplant* 2015;5:348-53.
280. Picano E, Pelliikka PA. Stress echo applications beyond coronary artery disease. *Eur Heart J* 2014;35:1033-40.

281. Venkateswaran RV, Townend JN, Wilson IC, Mascaro JG, Bonser RS, Steeds RP. Echocardiography in the potential heart donor. *Transplantation* 2010;89:894-901.
282. Dandel M, Lehmkühl H, Knosalla C, Suramelashvili N, Hetzer R. Strain and strain rate imaging by echocardiography - basic concepts and clinical applicability. *Curr Cardiol Rev* 2009;5:133-48.
283. Ingul CB, Torp H, Aase SA, Berg S, Stoylen A, Slordahl SA. Automated analysis of strain rate and strain: feasibility and clinical implications. *J Am Soc Echocardiogr* 2005;18:411-8.
284. Marwick TH. Measurement of strain and strain rate by echocardiography: ready for prime time? *J Am Coll Cardiol* 2006;47:1313-27.
285. Uematsu M, Miyatake K, Tanaka N, et al. Myocardial velocity gradient as a new indicator of regional left ventricular contraction: detection by a two-dimensional tissue Doppler imaging technique. *J Am Coll Cardiol* 1995;26:217-23.
286. D'Hooge J, Heimdal A, Jamal F, et al. Regional strain and strain rate measurements by cardiac ultrasound: principles, implementation and limitations. *Eur J Echocardiogr* 2000;1:154-70.
287. Edvardsen T, Gerber BL, Garot J, Bluemke DA, Lima JA, Smiseth OA. Quantitative assessment of intrinsic regional myocardial deformation by Doppler strain rate echocardiography in humans: validation against three-dimensional tagged magnetic resonance imaging. *Circulation* 2002;106:50-6.
288. Cullen MW, Pellikka PA. Recent advances in stress echocardiography. *Curr Opin Cardiol* 2011;26:379-84.
289. Jenkins C, Moir S, Chan J, Rakhit D, Haluska B, Marwick TH. Left ventricular volume measurement with echocardiography: a comparison of left ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging. *Eur Heart J* 2009;30:98-106.
290. Chaves AH, Cava JR, Simpson P, Hoffman GM, Samyn MM. Infant cardiac magnetic resonance imaging using oscillatory ventilation: safe and effective. *Pediatr Cardiol* 2013;34:1201-5.
291. Camarda J, Saudek D, Tweddell J, et al. MRI validated echocardiographic technique to measure total cardiac volume: a tool for donor-recipient size matching in pediatric heart transplantation. *Pediatr Transplant* 2013;17:300-6.
292. Messer S, Lannon J, Wong E, et al. The potential of transplanting hearts from donation after circulatory determined death (DCD) donors within the United Kingdom. *J Heart Lung Transplant* 2015;34:S275.
293. Noterdaeme T, Detry O, Hans MF, et al. What is the potential increase in the heart graft pool by cardiac donation after circulatory death? *Transpl Int* 2013;26:61-6.
294. Khush KK. Donor selection in the modern era. *Ann Cardiothorac Surg* 2018;7:126-34.
295. Dorent R, Gandjbakhch E, Goéminne C, et al. Assessment of potential heart donors: a statement from the French heart transplant community. *Arch Cardiovasc Dis* 2018;111:126-39.
296. Miranda B, Segovia C, Sanchez M, Felipe C, Naya MT, Matesanz R. Evolution of organ procurement and donor characteristics in Spain. *Transplant Proc* 1995;27:2384-8.
297. Zaroff JG, Babcock WD, Shiboski SC. The impact of left ventricular dysfunction on cardiac donor transplant rates. *J Heart Lung Transplant* 2003;22:334-7.
298. Dujardin KS, McCully RB, Wijdicks EF, et al. Myocardial dysfunction associated with brain death: clinical, echocardiographic, and pathologic features. *J Heart Lung Transplant* 2001;20:350-7.
299. Madan S, Saeed O, Vlismas P, et al. Outcomes after transplantation of donor hearts with improving left ventricular systolic dysfunction. *J Am Coll Cardiol* 2017;70:1248-58.
300. Kono T, Nishina T, Morita H, Hirota Y, Kawamura K, Fujiwara A. Usefulness of low-dose dobutamine stress echocardiography for evaluating reversibility of brain death-induced myocardial dysfunction. *Am J Cardiol* 1999;84:578-82.
301. Garcia-Dorado D, Andres-Villarreal M, Ruiz-Meana M, Inseste J, Barba I. Myocardial edema: a translational view. *J Mol Cell Cardiol* 2012;52:931-9.
302. Kobashigawa J, Khush K, Colvin M, et al. Report from the American Society of Transplantation Conference on donor heart selection in adult cardiac transplantation in the United States. *Am J Transplant* 2017;17:2559-66.
303. Kransdorf EP, Kittleson MM, Benck LR, et al. Predicted heart mass is the optimal metric for size match in heart transplantation. *J Heart Lung Transplant* 2019;38:156-65.
304. Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. *J Heart Lung Transplant* 2016;35:1-23.
305. Ziaziaris W, Chew HC, Dhital K, Hayward C, Pleass H, Macdonald P. Size and gender matching in heart transplantation - optimizing donor utilization in an era of changing donor and recipient characteristics. *Curr Transplant Rep* 2014;1:266-72.
306. Organ Procurement and Transplantation Network. Deceased Donors Recovered in the U.S. by Donor Age; 2018. <https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/>.
307. Estevez-Loureiro R, Paniagua-Martín MJ, Calviño-Santos R, et al. Prevalence of donor-transmitted coronary artery disease and its influence on heart transplant outcomes. *Transplant Proc* 2010;42:2987-91.
308. Pinto CS, Prieto D, Antunes MJ. Coronary artery bypass graft surgery during heart transplantation. *Interact Cardiovasc Thorac Surg* 2013;16:224-5.
309. Abid Q, Parry G, Forty J, Dark JH. Concurrent coronary grafting of the donor heart with left internal mammary artery: 10-year experience. *J Heart Lung Transplant* 2002;21:812-4.
310. Marelli D, Laks H, Bresson S, et al. Results after transplantation using donor hearts with preexisting coronary artery disease. *J Thorac Cardiovasc Surg* 2003;126:821-5.
311. Pawale A, Tang GH, Milla F, Pinney S, Adams DH, Anyanwu AC. Bench mitral valve repair of donor hearts before orthotopic heart transplantation. *Circ Heart Fail* 2012;5:e96-7.
312. Floerchinger B, Oberhuber R, Tullius SG. Effects of brain death on organ quality and transplant outcome. *Transplant Rev (Orlando)* 2012;26:54-9.
313. Mohamedali B, Bhat G, Zelinger A. Frequency and pattern of left ventricular dysfunction in potential heart donors: Implications regarding use of dysfunctional hearts for successful transplantation. *J Am Coll Cardiol* 2012;60:235-6.
314. Sztark F, Thicoipé M, Lassié P, Petitjean ME, Dabadie P. Mitochondrial energy metabolism in brain-dead organ donors. *Ann Transplant* 2000;5:41-4.
315. Khush KK, Zaroff JG, Nguyen J, Menza R, Goldstein BA. National decline in donor heart utilization with regional variability: 1995-2010. *Am J Transplant* 2015;15:642-9.
316. Chen CW, Sprys MH, Gaffey AC, et al. Low ejection fraction in donor hearts is not directly associated with increased recipient mortality. *J Heart Lung Transplant* 2017;36:611-5.
317. Antunes PE, Prieto D, Eugénio L, Antunes MJ. Donor mitral valve repair in cardiac transplantation. *J Thorac Cardiovasc Surg* 2005;129:227-8.
318. Coskun KO, Coskun ST, El Arousy M, et al. Cardiac surgery after heart transplantation: coronary artery bypass grafting and heart valve replacement. *Heart Surg Forum* 2007;10:E110-4.
319. Fiore A, Grande AM, Gatti G, et al. Valvular surgery in donor hearts before orthotopic heart transplantation. *Arch Cardiovasc Dis* 2020;113:674-8.
320. Flécher E. Valvular surgery before cardiac transplantation: the exception that proves the rule. *Arch Cardiovasc Dis* 2020;113:671-3.
321. Larobina ME, Mariani JA, Rowland MA. Aortic valve replacement for aortic stenosis during orthotopic cardiac transplant. *Ann Thorac Surg* 2008;86:1979-82.
322. Massad MG, Smedira NG, Hobbs RE, Hoercher K, Vandervoort P, McCarthy PM. Bench repair of donor mitral valve before heart transplantation. *Ann Thorac Surg* 1996;61:1833-5.
323. Patel M, Vahdat KK, Nathan S, et al. Bioprosthetic aortic valve replacement in a donor heart before orthotopic heart transplantation. *Tex Heart Inst J* 2017;44:135-7.
324. Risher WH, Ochsner JL, Van Meter C. Cardiac transplantation after donor mitral valve commissurotomy. *Ann Thorac Surg* 1994;57:221-2.

325. Saito S, Matsumiya G, Ueno T, et al. Bench replacement of donor aortic valve before orthotopic heart transplantation. *J Heart Lung Transplant* 2009;28:981-3.
326. Sprengel A, Skwara W, Ziegelhöffer T, Cetinkaya A, Schönburg M, Richter M. Combined mitral valve repair and heart transplantation. *Clin Case Rep* 2018;6:564-8.
327. de Beco G, Duisit J, Poncelet AJ. Heart transplantation using a donor with partial anomalous pulmonary venous connection and atrial septal defect. *Interact Cardiovasc Thorac Surg* 2017;24:978-9.
328. Loebe M, Koerner MM, Zener J, Lafuente JA, Torre-Amione G, Noon GP. Use of a donor heart that had undergone previous cardiac surgery for ASD closure. *J Heart Lung Transplant* 2002;21:294-5.
329. Lee GS, Goldberg DS, Levine MH, Abt PL. Outcomes of organ transplants when the donor is a prior recipient. *Am J Transplant* 2018;18:492-503.
330. Yang HY, Lin CY, Tsai YT, Lee CY, Tsai CS. Experience of heart transplantation from hemodynamically unstable brain-dead donors with extracorporeal support. *Clin Transplant* 2012;26:792-6.
331. Singh G, Tsukashita M, Biscotti M, et al. Heart procurement from a donor on venovenous ECMO support. *Asaio j* 2016;62:e24-6.
332. Shudo Y, Ma M, Boyd JH, Woo YJ. Current status of domino heart transplantation. *J Card Surg* 2017;32:229-32.
333. International Society for Heart Lung Transplantation. International Thoracic Organ Transplant (ITOT) Registry data slides; 2014. <https://ishltregistries.org/registries/slides.asp>.
334. Anyanwu AC, Banner NR, Mitchell AG, Khaghani A, Yacoub MH. Low incidence and severity of transplant-associated coronary artery disease in heart transplants from live donors. *J Heart Lung Transplant* 2003;22:281-6.
335. Bisoyi S, Jagannathan U, Dash AK, et al. Isolated persistent left superior vena cava: a case report and its clinical implications. *Ann Card Anaesth* 2017;20:104-7.
336. Goyal SK, Punnam SR, Verma G, Ruberg FL. Persistent left superior vena cava: a case report and review of literature. *Cardiovasc Ultrasound* 2008;6:50.
337. Heye T, Wengenroth M, Schipp A, Johannes Dengler T, Grenacher L, Werner Kauffmann G. Persistent left superior vena cava with absent right superior vena cava: morphological CT features and clinical implications. *Int J Cardiol* 2007;116:e103-5.
338. Jacob M, Sokoll A, Mannherz HG. A case of persistent left and absent right superior caval vein: an anatomical and embryological perspective. *Clin Anat* 2010;23:277-86.
339. Zhong YL, Long XM, Jiang LY, et al. Surgical treatment of Dextroversion, isolated persistent left superior vena cava draining into the left atrium. *J Card Surg* 2015;30:767-70.
340. Corici OM, Gaspar M, Mornoş A, Iancău M. Cardiac arrhythmias in patient with isolated persistent left superior vena cava. *Curr Health Sci J* 2017;43:163-6.
341. Morgan LG, Gardner J, Calkins J. The incidental finding of a persistent left superior vena cava: implications for primary care providers—case and review. *Case Rep Med* 2015;2015:198754.
342. Miraldi F, di Gioia CR, Proietti P, De Santis M, d'Amati G, Gallo P. Cardinal vein isomerism: an embryological hypothesis to explain a persistent left superior vena cava draining into the roof of the left atrium in the absence of coronary sinus and atrial septal defect. *Cardiovasc Pathol* 2002;11:149-52.
343. Pasquini L, Belmar C, Seale A, Gardiner HM. Prenatal diagnosis of absent right and persistent left superior vena cava. *Prenat Diagn* 2006;26:700-2.
344. Dinasarapu CR, Adiga GU, Malik S. Recurrent cerebral embolism associated with indwelling catheter in the presence of anomalous neck venous structures. *Am J Med Sci* 2010;340:421-3.
345. Granata A, Andrulli S, Fiorini F, et al. Persistent left superior vena cava: what the interventional nephrologist needs to know. *J Vasc Access* 2009;10:207-11.
346. Povoski SP, Khabiri H. Persistent left superior vena cava: Review of the literature, clinical implications, and relevance of alterations in thoracic central venous anatomy as pertaining to the general principles of central venous access device placement and venography in cancer patients. *World J Surg Oncol* 2011;9:173.
347. Pretorius PM, Case Gleeson FV. 74: right-sided superior vena cava draining into left atrium in a patient with persistent left-sided superior vena cava. *Radiology* 2004;232:730-4.
348. Paval J, Nayak S. A persistent left superior vena cava. *Singapore Med J* 2007;48:e90-3.
349. Angelini P. Coronary artery anomalies: an entity in search of an identity. *Circulation* 2007;115:1296-305.
350. Agarwal PP, Dennie C, Pena E, et al. Anomalous coronary arteries that need intervention: review of pre- and postoperative imaging appearances. *Radiographics* 2017;37:740-57.
351. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. *Circulation* 2009;119:1085-92.
352. Lim JC, Beale A, Ramcharitar S. Anomalous origination of a coronary artery from the opposite sinus. *Nat Rev Cardiol* 2011;8:706-19.
353. Angelini P, Villason S, Chan AV, Diez JG. Normal and anomalous coronary arteries in humans. In: Angelini P, ed. *Coronary Artery Anomalies: A Comprehensive Approach*, Philadelphia: Lippincott Williams & Wilkins; 1999:27-79.
354. Bresseleers D, Flameng W, Vanhaecke J. Anomalous origin of a coronary artery in a transplanted heart. *Acta Cardiol* 1999;54:93-6.
355. Angelini P. Coronary artery anomalies—current clinical issues: definitions, classification, incidence, clinical relevance, and treatment guidelines. *Tex Heart Inst J* 2002;29:271-8.
356. Yamanaka O, Hobbs RE. Coronary artery anomalies in 126,595 patients undergoing coronary arteriography. *Cathet Cardiovasc Diagn* 1990;21:28-40.
357. Madea B, Dettmeyer R. Sudden death in cases with anomalous origin of the left coronary artery. *Forensic Sci Int* 1998;96:91-100.
358. Patterson FK. Sudden death in a young adult with anomalous origin of the posterior circumflex artery. *South Med J* 1982;75:748-9.
359. Koutroulou I, Tsvigoulis G, Tsalikakis D, Karacostas D, Grigoriadis N, Karapanayiotides T. Epidemiology of Patent foramen ovale in general population and in stroke patients: a narrative review. *Front Neurol* 2020;11:281.
360. Bapat A, Recto MR, Bhat G. Transcatheter closure of a patent foramen ovale in an adult with hypoxemia after cardiac transplantation. *Tex Heart Inst J* 2004;31:175-7.
361. Ouseph R, Stoddard MF, Lederer ED. Patent foramen ovale presenting as refractory hypoxemia after heart transplantation. *J Am Soc Echocardiogr* 1997;10:973-6.
362. Schulman LL, Smith CR, Drusin R, Rose EA, Enson Y, Reemtsma K. Patent foramen ovale complicating heart transplantation. A window on posttransplantation hemodynamics. *Chest* 1987;92:569-72.
363. Rigatelli G, Cardaioli P, Faggian G. Patent foramen ovale management before and after heart transplantation: a simple algorithm. *J Heart Lung Transplant* 2007;26:961-2.
364. Hsieh EM, Blackstone EH, Thuita LW, et al. Heart transplantation: an in-depth survival analysis. *JACC Heart Fail* 2020;8:557-68.
365. Smits JM, de Vries E, De Pauw M, et al. Is it time for a cardiac allocation score? First results from the Eurotransplant pilot study on a survival benefit-based heart allocation. *J Heart Lung Transplant* 2013;32:873-80.
366. Dipchand AL, Mahle WT, Tresler M, et al. Extracorporeal membrane oxygenation as a bridge to pediatric heart transplantation: effect on post-listing and post-transplantation outcomes. *Circ Heart Fail* 2015;8:960-9.
367. Russo MJ, Iribarne A, Easterwood R, et al. Post-heart transplant survival is inferior at low-volume centers across all risk strata. *Circulation* 2010;122(11 Suppl):S85-91.
368. Weiss ES, Allen JG, Arnaoutakis GJ, et al. Creation of a quantitative recipient risk index for mortality prediction after cardiac transplantation (IMPACT). *Ann Thorac Surg* 2011;92:914-21. discussion 921-912.
369. Zalawadiya S, Fudim M, Bhat G, Cotts W, Lindenfeld J. Extracorporeal membrane oxygenation support and post-heart transplant outcomes among United States adults. *J Heart Lung Transplant* 2017;36:77-81.
370. Aleksova N, Alba AC, Molinero VM, et al. Risk prediction models for survival after heart transplantation: a systematic review. *Am J Transplant* 2020;20:1137-51.

371. Kutschmann M, Fischer-Fröhlich CL, Schmidtman I, et al. The joint impact of donor and recipient parameters on the outcome of heart transplantation in Germany after graft allocation. *Transpl Int* 2014;27:152-61.
372. Parker WF, Garrity ER, Fedson S, Churpek MM. Trends in the use of inotropes to list adult heart transplant candidates at status 1A. *Circ Heart Fail* 2017;10:e004483. <https://doi.org/10.1161/CIRCHEARTFAILURE.117.004483>.
373. Stevenson LW, Kormos RL, Young JB, Kirklin JK, Hunt SA. Major advantages and critical challenge for the proposed United States heart allocation system. *J Heart Lung Transplant* 2016;35:547-9.
374. Anyanwu AC, Rogers CA, Murday AJ. A simple approach to risk stratification in adult heart transplantation. *Eur J Cardiothorac Surg* 1999;16:424-8.
375. Nilsson J, Ohlsson M, Höglund P, Ekmehag B, Koul B, Andersson B. The International Heart Transplant Survival Algorithm (IHTSA): a new model to improve organ sharing and survival. *PLoS One* 2015;10:e0118644.
376. Johnston LE, Grimm JC, Magruder JT, Shah AS. Development of a transplantation risk index in patients with mechanical circulatory support: a decision support tool. *JACC Heart Fail* 2016;4:277-86.
377. Trivedi JR, Cheng A, Ising M, Lenneman A, Birks E, Slaughter MS. Heart transplant survival based on recipient and donor risk scoring: a UNOS database analysis. *Asaio j* 2016;62:297-301.
378. Joyce DL, Li Z, Edwards LB, Kobashigawa JA, Daly RC. Predicting 1-year cardiac transplantation survival using a donor-recipient risk-assessment tool. *J Thorac Cardiovasc Surg* 2018;155:1580-90.
379. Yoon J, Zame WR, Banerjee A, Cadeiras M, Alaa AM, van der Schaar M. Personalized survival predictions via trees of predictors: an application to cardiac transplantation. *PLoS One* 2018;13:e0194985.
380. Vania DK, Randall GE. Can evidence-based health policy from high-income countries be applied to lower-income countries: considering barriers and facilitators to an organ donor registry in Mumbai, India. *Health Res Policy Syst* 2016;14:3.
381. Mizraji R, Godino M, Tommasino N, Alvarez I. Donation rates: what matters? *Transplant Proc* 2014;46:2940-4.
382. Abadie A, Gay S. The impact of presumed consent legislation on cadaveric organ donation: a cross-country study. *J Health Econ* 2006;25:599-620.
383. Arshad A, Anderson B, Sharif A. Comparison of organ donation and transplantation rates between opt-out and opt-in systems. *Kidney Int* 2019;95:1453-60.
384. Berzon C. Israel's 2008 Organ Transplant Law: continued ethical challenges to the priority points model. *Isr J Health Policy Res* 2018;7:11.
385. Chin JJ, Kwok TH. After presumed consent: a review of organ donation in Singapore. *Indian J Med Ethics* 2014;11:139-43.
386. Cronin AJ. Points mean prizes: priority points, preferential status and directed organ donation in Israel. *Isr J Health Policy Res* 2014;3:8.
387. Domínguez J, Rojas JL. Presumed consent legislation failed to improve organ donation in Chile. *Transplant Proc* 2013;45:1316-7.
388. Dutt A. Heart transplants picking up in India: 10-fold increase since 2016. 2018; <https://www.hindustantimes.com/health/heart-transplants-picking-up-in-india-10-fold-increase-since-2016/story-xebwOoZCIC877atM4C0sEO.html>.
389. Einollahi B. Cadaveric kidney transplantation in Iran: behind the Middle Eastern countries? *Iran J Kidney Dis* 2008;2:55-6.
390. Fabre J. Presumed consent for organ donation: a clinically unnecessary and corrupting influence in medicine and politics. *Clin Med (Lond)* 2014;14:567-71.
391. Fabre J, Murphy P, Matesanz R. Presumed consent: a distraction in the quest for increasing rates of organ donation. *Bmj* 2010;341:c4973.
392. Fukushima N, Ono M, Nakatani T, Minami M, Konaka S, Ashikari J. Strategies for maximizing heart and lung transplantation opportunities in Japan. *Transplant Proc* 2009;41:273-6.
393. Hawkes N. Welsh opt-out law fails to increase organ donations. *Bmj* 2017;359:j5659.
394. Kiani M, Abbasi M, Ahmadi M, Salehi B. Organ Transplantation in Iran; current state and challenges with a view on ethical consideration. *J Clin Med* 2018;7:45. <https://doi.org/10.3390/jcm7030045>.
395. Kitamura T, Torii S, Oka N, et al. Seventeen-month-long paracorporeal biventricular mechanical support as a bridge to transplantation for severe dilated cardiomyopathy. *J Artif Organs* 2015;18:92-4.
396. Matesanz R, Domínguez-Gil B, Coll E, Mahillo B, Marazuela R. How Spain reached 40 deceased organ donors per million population. *Am J Transplant* 2017;17:1447-54.
397. Matesanz R, Marazuela R, Coll E, Mahillo B, Domínguez-Gil B. About the opt-out system, live transplantation, and information to the public on organ donation in Spain ... Y olé!. *Am J Transplant* 2017;17:1695-6.
398. Meyer DM, Rogers JG, Edwards LB, et al. The future direction of the adult heart allocation system in the United States. *Am J Transplant* 2015;15:44-54.
399. Mizraji R, Alvarez I, Palacios RI, et al. Organ donation in Latin America. *Transplant Proc* 2007;39:333-5.
400. Sharif A. Viva España-Lessons from the Spanish organ donation system. *Am J Transplant* 2017;17:1694.
401. Sharif A. Presumed consent will not automatically lead to increased organ donation. *Kidney Int* 2018;94:249-51.
402. Stoler A, Kessler JB, Ashkenazi T, Roth AE, Lavee J. Incentivizing authorization for deceased organ donation with organ allocation priority: the first 5 years. *Am J Transplant* 2016;16:2639-45.
403. Vertanous T, Czer LS, de Robertis M, et al. Leading efforts to increase organ donation through professionalization of organ procurement organizations and establishment of organ and tissue donor registries. *Transplant Proc* 2016;48:10-4.
404. Wise J. Organ donation: opt-out system should be in place by 2020 in England. *Bmj* 2018;362:k3414.
405. Wu X, Fang Q. Financial compensation for deceased organ donation in China. *J Med Ethics* 2013;39:378-9.
406. Zúñiga-Fajuri A. Increasing organ donation by presumed consent and allocation priority: Chile. *Bull World Health Organ* 2015;93:199-202.
407. Mehra MR, Jarcho JA, Cherikh W, et al. The drug-intoxication epidemic and solid-organ transplantation. *N Engl J Med* 2018;378:1943-5.
408. Roudot-Thoraval F, Romano P, Spaak F, Houssin D, Durand-Zaleski I. Geographic disparities in access to organ transplant in France. *Transplantation* 2003;76:1385-8.
409. Matas AJ, Satel S, Munn S, et al. Incentives for organ donation: proposed standards for an internationally acceptable system. *Am J Transplant* 2012;12:306-12.
410. Delmonico FL, Martin D, Domínguez-Gil B, et al. Living and deceased organ donation should be financially neutral acts. *Am J Transplant* 2015;15:1187-91.
411. Masri M, Haberal M. Solid-organ transplant activity in MESOT countries. *Exp Clin Transplant* 2013;11:93-8.
412. Capron AM, Delmonico FL, Domínguez-Gil B, Martin DE, Danovitch GM, Chapman J. Statement of the declaration of Istanbul custodian group regarding payments to families of deceased organ donors. *Transplantation* 2016;100:2006-9.
413. Giorgakis E, Singer AL, Khorsandi SE, Prachalias A. Transplantation crisis at the time of economic recession in Greece. *Public Health* 2018;160:125-8.
414. World Health Organization. WHO guiding principles on human cell, tissue and organ transplantation. *Cell Tissue Bank* 2010;11:413-9.